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Abstract
Inflammation is a crucial defense mechanism that protects the body from the effect of
invading pathogens. However, the inflammatory response needs to be controlled in
order to avoid systemic manifestations with serious consequences to the host.
Accumulating evidence indicates that the inflammatory response is tightly regulated
through immunological and neural pathways. Previously, it has been demonstrated that
cholinergic stimulation by paraoxon, a specific and irreversible inhibitor of
acetylcholinesterase (AChE), improved survival in mice following an oral infection
with virulent Salmonella enterica serovar Typhimurium (S. typhimurium). However,
paraoxon is an organophosphorous compound unsuited for human use. In this study,
the main objective is to investigate the efficiency of rivastigmine, an FDA-approved
inhibitor of AChE, on murine mucosal defenses in the gastrointestinal (GI) tract
against Salmonella infections. Results show that cholinergic stimulation with
rivastigmine enhanced host survival following an oral-route infection, and this
correlated with lower bacterial load in systemic organs, including liver and spleen.
Interestingly, while bacterial loads in systemic organs were decreased, bacterial loads
were higher in intestinal content and feces compared to saline control group,
suggesting enhanced bacterial shedding in the GI tract. Morphological analysis of the
small intestine (ileum) showed that rivastigmine induced the degranulation of goblet
cells and Paneth cells, two specialized secretory cells involved in innate immunity, and
demonstrated a significant increase in the thickness of mucin layer in these mice.
Immunohistochemical study of the immune population present at the intestinal mucosa
revealed that rivastigmine treatment resulted in minor changes in the lymphoid
population in the epithelium (intraepithelial lymphocytes or IELs) and lamina propria
(LP). A comparative flowcytometric analysis of the different leukocytic populations
present in the two isolated compartments of the intestinal mucosa (IEL and LP)
following either paraoxon or rivastigmine treatment, demonstrated that only paraoxon
induced an increase in the CD8+ population in the LP. Moreover, intestinal epithelium
of rivastigmine-treated mice presented a decrease in CD8+TCR+ cells. These
findings indicate that rivastigmine-mediated cholinergic modulation increases the
innate defense mechanisms at the level of the intestinal lumen, delaying the bacterial
translocation from intestine to LP and systemic organs, ultimately leading to enhanced
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initial protection against a lethal bacterial infection. However, complete protection in
this model appears to require the recruitment of professional T cells to the LP, which
was only observed after treatment with irreversible AChE inhibitors, like paraoxon.
The data highlight the crucial interactions between neural and immune systems that
act at the GI mucosal interface to protect the host against invading pathogens.
Keywords: Acetylcholinesterase Inhibition, Salmonella enterica, Neuro-immune,
Intestine, Mucosal Barrier, Goblet Cells, Paneth Cells, Intestinal Epithelium, Lamina
Propria.
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)Title and Abstract (in Arabic

تحوير الدفاعات المضادة للميكروبات في الجهاز الهضمي بواسطة مثبطات األستيل
كولينيستراز
الملخص

يعد االلتهاب آلية دفاعية مهمة تحمي الجسم من تأثير غزو مسببات األمراض .ومع ذلك ،يجب
السيطرة على االستجابة االلتهابية من أجل تجنب المظاهر الجهازية مع عواقب وخيمة على
المضيف .تشير األدلة المتراكمة إلى أن االستجابة االلتهابية يتم تنظيمها بإحكام من خالل
المسارات المناعية والعصبية .في السابق ،لقد أثبت أن رفع مستوى الناقل العصبي االستيل كولين
عن طريق الباروكسون ،وهو مثبط محدد ال رجعة فيه ألسيتيل كولينيستراز) ،(AChEأدى إلى
حماية الفئران من عدوى السالمونيال القاتلة مع ذلك ،فإن الباروكسون مركب فوسفور عضوي
غير مناسب لالستخدام البشري .في هذه الدراسة ،استهدفنا دراسة كفاءة عقار ريفاستغمين ،وهو
مثبط معتمد من إدارة األغذية والعقاقير لـ  ،AChEعلى دفاعات الغشاء المخاطي للفأر في الجهاز
الهضمي ضد عدوى السالمونيال .أثبتنا أن رفع مستوى الناقل العصبي االستيل كولين عن طريق
ريفاستغمين يعزز بقاء الفئران بعد اإلصابة البكتيرية عن طريق الفم ،وهذا يرتبط مع انخفاض
التعداد الجرثومي في األعضاء الرئيسية ،بما في ذلك الكبد والطحال .ومن المثير لالهتمام ،أنه
بينما انخفض التعداد الجرثومي في الكبد والطحال ،كانت البكتيريا أعلى في محتوى األمعاء
والبراز مقارنة بمجموعة الفئران التي لم تأخذ العقار ،مما يشير إلى تخلص الجسم من البكتيريا
المعززة في الجهاز الهضمي .وأظهر التحليل المورفولوجي لألمعاء الدقيقة أن ريفاستغمين تسبب
في تحلل خاليا الكأس وخاليا البانث ،وهما خليتان إفرازيتان متخصصتان في المناعة األولية،
وأظهروا زيادة كبيرة في سمك الغشاء المخاطي في هذه الفئران .وكشفت دراسة كيميائية مناعية
في األمعاء أن عالج ريفاستغمين أدى إلى تغييرات طفيفة في الخاليا المناعية الموجودة في )(IEL
 .(LP) andأظهر تحليل مقاييس التدفق المقارن لمختلف كرات الدم البيضاء الموجودة في
الجزءين المعزولين من الغشاء المخاطي في األمعاء (الظهارة و بروبريا الصفيحة) بعد العالج
بالباروكسون أو ريفاستغمين ،أن الباروكسون هو الذي تسبب فقط في زيادة عدد سكان CD8 +
في بروبريا المينا .وعالوة على ذلك ،قدمت ظهارة معوية من الفئران المعالجة ريفاستغمين
انخفاض في خاليا  .CD8+TCR+تشير هذه النتائج إلى أن التحوير الكوليني الذي يتوسطه
ريفاستغمين يزيد من آليات الدفاع الفطرية على مستوى التجويف المعوي ،مما يؤخر االنتقال
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البكتيري من األمعاء إلى بروبريا الصفيحة واألعضاء الجهازية ،مما يؤدي في النهاية إلى تعزيز
الحماية األولية ضد العدوى البكتيرية الفتاكة .ومع ذلك ،لتحقيق الحماية الكاملة في هذا النموذج،
يبدو أنه من الضروري توظيف خاليا  Tاحترافية في بروبريا الصفيحة التي يتم تحقيقها فقط بعد
العالج بمثبطات  ACHEالتي ال رجعة فيها مثل الباروكسون .تسلط البيانات الضوء على
التفاعالت الحاسمة بين الجهاز العصبي والجهاز المناعي التي تعمل عند واجهة الجهاز الهضمي
المخاطية لحماية المضيف من مسببات األمراض.
مفاهيم البحث الرئيسية :مثبطات األستيل كولين استيراز ،السالمونيال انتريكا ،المناعة العصبية،
األمعاء ،حاجز الغشاء المخاطي ،خاليا الكأس ،خاليا البانث ،ظهارة األمعاء ،بروبريا المينا.
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Chapter 1: Introduction
1.1 Neuronal nervous system
The nervous system is a complex network of nerves and cells that enables an organism
to interact with its surroundings. The nervous system has two components: the central
nervous system and the peripheral nervous system. The central nervous system
includes the brain and the spinal cord. The peripheral nervous system is divided into:
•

Somatic nervous system.

•

Autonomic nervous system.

The somatic nervous system is in charge of the voluntary movements. It consists of
the (a) afferent branch that transmits sensory information from the periphery to the
brain, and the (b) efferent branch that carries the information from the brain to the
muscles causing their movements.
The autonomic nervous system controls and regulates involuntary functions of
internal organs. It contains three different divisions:
•

The sympathetic nervous system (SNS).

•

The parasympathetic nervous system (PNS).

•

The enteric nervous system (ENS).

The sympathetic nervous system innervates almost every tissue in the body and its
activation leads to an overall increase activity and attention, what is called the “fight
or flight” response (Koopman et al., 2011). The parasympathetic nervous system is
smaller than the SNS and innervates only the head, viscera and external genitals.
Opposite to the SNS, the PNS promotes “rest and digest” processes (Kenney & Ganta,
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2014; Koopman et al., 2011) through the vagus nerve, its major nerve. The enteric
nervous system is the most complex division of the peripheral nervous system
(Gershon & Erde, 1981). It is composed of a network of neurons embedded into the
wall of the gut forming two plexuses: the myenteric, located between the longitudinal
and circular smooth muscle of the GI tract, and the submucosal, present in the GI
submucosa (Waxenbaum & Varacallo, 2019).
The neurotransmitters used for the SNS are norepinephrine (presynaptic neurons) and
acetylcholine (postsynaptic neurons). The PNS uses exclusively acetylcholine (ACh)
and the ENS is known to use several neurotransmitter like ACh, nitrous oxide and
serotonin (Koopman et al., 2011; McConalogue & Furness, 1994).
ACh was the first neurotransmitter identified in 1926 by Otto Loewi who received,
together with Sir Henry Dale (who first isolated ACh from an animal organ), the Nobel
prize in Medicine in 1936 (Fujii et al., 2017a). In the following years, the neuronal
cholinergic system was explored and ACh was recognized as the neurotransmitter in
the postganglionic parasympathetic system, the preganglionic neurons of the
sympathetic system, the human axilla sweat glands and several brain regions.
Acetylcholine is the essential neurotransmitter of the parasympathetic nervous systems
(Lott & Jones, 2019). It is synthesized in the presynaptic neurons by the enzyme
choline acetyltransferase (ChAT) from acetyl CoA and choline. Then, ACh is stored
in secretory vesicles, where it enters with the help of the vesicular acetylcholine
transporters (VAChT). Upon neuronal stimulation and membrane depolarization, ACh
is released to the synaptic cleft where it binds to its receptors expressed in the
postsynaptic membrane. In the cleft, and soon after its secretion, acetylcholine is
hydrolyzed and converted into the inactive metabolites, choline and acetic acid, by the
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enzyme acetylcholinesterase (AChE). Choline is then reabsorbed through a highaffinity choline transporter into the pre-synaptic neuron to be reused for ACh synthesis
(Kawashima & Fujii, 2008). Figure 1 demonstrates the life cycle of ACh.

Figure 1: Acetylcholine life cycle. Acetylcholine is made from choline and acetyl CoA
in the cytoplasm of the cell and stored inside secretory vesicles. Upon stimulation,
ACh is released to the cleft where it binds to its receptors and soon hydrolyzed by the
acetylcholinesterase enzyme into acetate and choline. Choline is transported back into
the axon terminal to be used again for the synthesis of ACh (Blog, 2014).

Some drugs act as acetylcholinesterase inhibitors, causing the accumulation of
acetylcholine in the cleft and, therefore, a hyperstimulation of the postsynaptic cell.
There are two types of ACh receptors: nicotinic acetylcholine receptors (nAChR) and
muscarinic acetylcholine receptors (mAChR). nAChRs are ligand-gated ion channels
composed of five protein subunits that are arranged symmetrically like staves around
a barrel. The subunit composition is totally different between different tissues. The
nAChR subunits in neurons may be either α (ranging from α2 to α10) or β (ranging
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from β2 to β4) and can be arranged as homomeric receptors such as α7 nAChR or
heteromeric receptors such as (α4)2(β2)3. nAChR in muscles cells is an heteromeric
structure composed of 2 α1 subunits and one of each of β1, γ (or ε) and δ (AbreuVillaça, Filgueiras, & Manhães, 2011; Kawashima & Fujii, 2008). mAChRs are Gprotein-coupled receptors categorized into five subtypes (M1, M2, M3, M4 and M5)
that differ in their distribution in the central and peripheral nervous systems and in
various organs and cells (Abreu-Villaça et al., 2011).
1.2 Non-neuronal cholinergic system
The word cholinergic refers to a system that not only uses the neurotransmitter
acetylcholine (ACh) to communicate, but also is able to synthesize ACh, ACh
transporters, ACh receptors and the enzymes for its degradation. In perspective of
phylogenesis, before the nervous system was established, the non-neuronal cholinergic
system (NNCS) already existed in non-neuronal cells such as bacteria, algae and
protozoa (Wessler, Kirkpatrick, & Racke, 1999). In multicellular organisms, the skin
is one of the best-known cholinergic organs. But apart from the skin, the NNCS has
been described in many other organs such trachea, kidney, small and large intestines,
and its role in disorders has already been described (Beckmann & Lips, 2013). Almost
all types of cells seem to express cholinergic receptors, however, receptor expression
alone is not an indication of NNCS, rather than its capacity to synthesize and releasing
ACh. Cells that synthesize exclusively cholinergic receptors may serve as effector cells
for non-neuronally as well as neuronally synthesized and released ACh. Non-neuronal
cholinergic cells have the same molecular elements for synthesis and release of ACh
than neurons (Wessler, Kilbinger, Bittinger, Unger, & Kirkpatrick, 2003). Thus, the
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presence of an NNCS has to be classified before considering its involvement in organspecific disorders.
1.2.1 Integumentary system
The integument consists of the skin and its derivatives, such as glands, hair and nails.
In the skin, keratinocytes synthesize ACh in large quantities; a single keratinocyte is
able to synthesize and release an average of 2 x 10-17 mol ACh and 7 x 10-19 mol ACh
per minute, respectively (Grando, Kist, Qi, & Dahl, 1993). Moreover, keratinocytes
express muscarinic and nicotinic ACh receptors, AChE and the transporters needed
for an efficient auto-/paracrine cholinergic loop. NNCS in the skin regulates the
keratinocyte connection, proliferation, differentiation, apoptosis, adhesion and
migration (Grando, Pittelkow, & Schallreuter, 2006) which confers the NNCS an
important role on the maintenance of healthy skin. In fact, NNSC seems to play a role
in several dermatological diseases such Atopic dermatitis (Grando et al., 2006).
1.2.2 The digestive system
The digestive system comprises of pharynx, oesophagus, stomach, small and large
intestines, and glandular organs such as liver, pancreas and salivary glands. Many
cholinergic neurons innervate the digestive tract (Harrington, Hutson, & Southwell,
2010) and, therefore, there are many impacts that can contribute to neuronal rather
than non-neuronal ACh release. M2 and M3 mAChR are responsible for mediating
smooth muscle cell contraction in gastrointestinal tract, although they are less
abundant but, functionally, more relevant than M1,M4 and M5 mAChR (Ruggieri &
Braverman, 2013). Thuong Nguyen et al. (2000) showed that ChAT, AChE and
various nAChR subunits can be found in the oesophageal epithelium and reduced
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levels of ACh and signaling may result in reduced function of the oesophageal
sphincter and eventually gastro-oesophageal reflux disease (Saegusa et al., 2011).
Other studies reporter the involvement of the NNCS on cell-cell contact modulation
and the alteration of elements needed for the synthesis and release of ACh (CHT1,
ChAT, VAChT and OCT1) in the oesophageal mucosa under pathological conditions
(Wolf-Johnston et al., 2012).
Inflammatory bowel diseases like ulcerative colitis and Crohn's disease have showed
significantly reduced AChE activity and higher levels of miRNA-132, a posttranscriptional inhibitor of AChE (Maharshak et al., 2013). Interestingly, the response
to nicotine varies between patients with Crohn's disease or ulcerative colitis as
smoking clearly aggravates the symptoms for Crohn's disease (Hilsden, Hodgins,
Timmer, & Sutherland, 2000), but it appears to have protective role in ulcerative colitis
and may even decrease mucosal inflammation in this patients (De Jonge & Ulloa,
2007).
In patients with ulcerative colitis has been observed an increased expression of M2
mAChR in the colon epithelium and a downregulation of ChAT and α3-nAChR
(Richardson et al., 2003). Using a mouse model of experimental colitis, α7-nAChRdeficient mice experimented an increased in severity of intestinal inflammation which
confers to the α7-nAChRs a major role in inflammation (Ghia et al., 2009). The antiinflammatory response to α7-nAChR stimulation, is most likely mediated in the
intestine by resident immune cells expressing this receptor (Lakhan & Kirchgessner,
2011). In addition, the nAChR subunit α5 also appears to play a major role in colitis
as nAChR subunit α5-deficient mice presented an increased susceptibility to
experimental colitis (Orr-Urtreger, Kedmi, Rosner, Karmeli, & Rachmilewitz, 2005).
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1.3 Cholinergic system in the immune cells
Many studies have demonstrated that most immune cells, including T and B cells,
macrophages and dendritic cells (DCs), express the components required for the
effective and independent cholinergic system: muscarinic and nicotinic ACh receptors,
ChAT and AChE. Moreover, it has been suggested that the ACh produced by immune
cells may modulate the immune function by regulating cytokine and antibody
production (Fujii et al., 2017b).
1.3.1 ACh
ACh produced by immune cells was first described in human peripheral blood
mononuclear leukocyte (MNL) fraction, where the majority are lymphocytes with a
small fraction of monocyte (Kawashima, Kajiyama, Fujimoto, Oohata, & Suzuki,
1993; Kawashima, Oohata, Fujimoto, & Suzuki, 1989; Yamada, Fujii, & Kawashima,
1997). The detection of ACh in multiple human leukemic cell lines (Fujii et al., 1999;
Fujii et al., 1996) as well as rat T and B lymphocytes verified the existence of ACh in
immune cells (Rinner, Kawashima, & Schauenstein, 1998) which explained the
presence of ACh in the spleen, despite of the absence of a cholinergic innervation
(Fujii et al., 2017a). Moreover, the content of ACh in human leukemic T cell lines is
greater than those of B cell lines, pre-lymphoma cell lines, or monocytic cell lines
(Fujii et al., 1999; Kawashima & Fujii, 2000). Among rat lymphocytes, T cells had a
considerably greater ACh content than B cells; and CD4+ T cells produce more ACh
than CD8+ T cells (Rinner et al., 1998) and, as expected, higher content of ACh was
correlated with greater ChAT activity (Rinner & Schauenstein, 1993).
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1.3.2 ChAT
In 1993, Rinner and Schauenstein reported an ACh- synthesizing activity and the
presence of ChAT in rat T and B cells present in thymus, spleen and blood (Rinner &
Schauenstein, 1993). Later studies confirmed the presence of ChAT in T and B cells,
macrophages, and DCs (Kawashima, Yoshikawa, Fujii, Moriwaki, & Misawa, 2007;
Koarai et al., 2012) and their upregulation occurs in response to TLR agonists that
elicit MyD88-dependent signal transduction in a cell-intrinsic manner (Reardon et al.,
2013), indicating that immunological activation of T cells induces the upregulation of
ACh synthesis that modulates the immune function (Fujii et al., 2017a).
1.3.3 ACh receptors
1.3.3.1 mAChR
Five different mAChR have been identified (M1, M2, M3,M4 and M5) (Bonner,
Buckley, Young, & Brann, 1987; Bonner, 1989; Bonner, Young, Bran, & Buckley,
1988) and classified into two different groups based on their functional coupling (Fujii
et al., 2017a). M1, M3 and M5 are coupled to the Gq/11 protein mediating the
activation of PLC and, through second messengers, the release of Ca2+ from
intracellular stores (Eglen & Nahorski, 2000). The other 2 subtypes, M2 and M4, are
coupled to Gi/0 protein that mediates the inhibition of the adenylate cyclase and,
therefore reducing the cAMP formation (Felder, 1995; Migeon, Thomas, &
Nathanson, 1995). All subtypes of muscarinic AChR (M1, M2, M3,M4 and M5) have
been found in T and B lymphocytes, DC, and macrophages of human, mice and rats
(Fujii et al., 2017a; Kawashima, Fujii, Moriwaki, & Misawa, 2012; Kawashima et al.,
2007). Their pattern of expression and intensities on the immune cells is variable and
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dependent of their immunological status (Qian, Galitovskiy, Chernyavsky,
Marchenko, & Grando, 2011). Moreover, it has been shown that M5 mAChRs are
upregulated upon stimulation which suggest their involvement in the regulation of the
immune function (Fujii et al., 2017a).
1.3.3.2 Nicotinic
Nicotinic receptors are pentamers composed of 1-5 different subunits. They have been
described as 10  (1-10), 4  (1-4), , , and  nAChR subunits. In all nAChRs, at
least two copies of the  subunit are always present among the five subunits (Fujii et
al., 2017a). Upon activation of the nAChRs there is an increase in the permeability of
the membrane to Na+, K+ and Ca2+ which leads to depolarization and excitation of
the membrane. In immune cells, Ca2+ influx specially through the 7nAChRs results
in a strong anti-inflammatory effect on macrophages (Báez-Pagán, Delgado-Vélez, &
Lasalde-Dominicci, 2015; Corradi & Bouzat, 2016; De Jonge & Ulloa, 2007; Egea et
al., 2015). Most immune cells, including T cells, MNLs, DCs and macrophages
express nAChR subunits. In these cells, mRNAs encoding for nAChR α2, α5, α6, α7,
α9, α10 and β2 subunits were found to be expressed, while α3 and β3 were not encoded
in any immune cell (Fujii et al., 2017b; Grando, Kawashima, Kirkpatrick, Kummer, &
Wessler, 2015; Kawashima et al., 2012). Variable results have been reported for the
presence of mRNAs for nAChR with α4, α9 and β4 subunits, (Kawashima et al., 2007).
1.3.4 AChE
To terminate the activity of the ACh, the enzyme AChE hydrolyzes ACh molecules
into choline and acetate. This enzymatic breakdown takes place within few
milliseconds which does not give time to the ACh to diffuse to the surrounding tissues.
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Therefore, ACh must be released within the spaces where direct contact between cells
occurs. Studies on C57BL/6J mice showed expression of AChE mRNAs in
lymphocytes, bone marrow-derived DCs and macrophages (Kawashima et al., 2007).
However, the physiological relevance of AChE in immune cells is not fully
understood. Table 1 summarizes the present of cholinergic system in immune cells.

Table 1: Cholinergic system components in immune cells.
Immune cells

ACh

ChAT

AChR

AChE

T cells

√

√

√

√

B cells

√

√

√

-

Macrophages

-

√

√

√

DCs

-

√

√

√

1.4 Cholinergic modulation of the immune cells
In the body's response to infection, innate immune cells have an important protective
role. Macrophages and neutrophils are the first immune cells recruited to the sites of
infection where they have an effective function in the elimination of pathogens (Hurst
et al., 2001; Zhang & Wang, 2014). It has been shown that nicotinic agonists can block
the synthesis and release of the pro-inflammatory cytokines IL-1β, TNF-α, IL-6 and
HMGB1 in a dose-dependent manner from activated macrophages and macrophage
cell lines. However, anti-inflammatory cytokines such as IL-10 are not usually affected
(Borovikova et al., 2000; Sun et al., 2013; Wang et al., 2004; Wang et al., 2003). These
studies involved pretreatment with non-selective and α7 selective AChR agonist
followed by a challenge with LPS or another TLR-ligand to induce a cytokine
response, (Khan et al., 2012; Wang et al., 2004; Wang et al., 2003).
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Previous experiments suggested that nicotinic and muscarinic ACh receptors are
present in immune cells to regulate their immune function. In immune cells, specific
agonist stimulation of nAChR and mAChR induced an enhanced cytotoxicity, cGMP
formation and intracellular Ca2 + signaling (Kawashima & Fujii, 2000). Culture of
human leukemic T cell (CCRF-CEM) and B cell lines (Daudi) with ACh or mAChR
agonists, like bethanechol and oxotremorine-M, induced a rapid increase of Ca2+ and
up-regulation of C-fos expression, an intranuclear transcription regulator (Fujii &
Kawashima, 2000). Moreover, these effects were found to be blocked by atropine, an
antagonist for mAChRs (Kawashima et al., 2012). These findings suggested that ACh
produced by T cells binds to the mAChRs expressed on their own plasma membrane
or on other cells located nearby to activate nuclear C-fos signaling, acting as an
autocrine and/or paracrine factor.
Other studies showed cholinergic activity during antigen presentation to naïve CD4+
T cells. Naïve CD4 T cell are circulating until they recognize antigens presented on
MHC class II molecules in secondary lymphoid organs by mature DCs. Recognition
of antigen through specific receptors (TCRs) and interaction of CD80/CD86 (B7) costimulatory molecules via CD28 causes their activation. Following antigen
presentation, an upregulation of ChAT mRNA expression, ChAT activity, ACh, AChE
and M5 mAChRs was observed which indicates an active cholinergic activity upon
stimulation (Fujii, Watanabe, Fujimoto, & Kawashima, 2003; Fujii, Watanabe, Inoue,
& Kawashima, 2003; Kawashima & Fujii, 2003, 2004).
SLURP-1, a receptor protein that potentiates the α7nAChR (positive allosteric ligand)
was demonstrated to be involved in the control of immune function in thymus and
spleen, as well as peripheral blood MNLs, DCs and macrophages. Furthermore,
CD205+ SLURP-1+ DCs are surrounded by CD4+ T cells and other immune cells
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expressing markers for monocyte/macrophages, DCs and B cells indicating strong
association between SLURP-1+ DCs and CD4+ T cells, specific subtypes of DCs,
macrophages and B cells during antigen presentation and other immunological
reactions (Fukaya et al., 2012).
In vivo studies with α7nAChR-KO mice demonstrated an involvement of α7nAChR
in the negative regulation of the immune function. Activation of α7nAChR inhibited
the synthesis and release of pro-inflammatory cytokines (TNF, IFN and IL-6) in
spleen which, in turn, suppressed the production of IgG immunoglobulin (Fujii et al.,
2007). These supported the existence of a non-neuronal cholinergic system in the
immune cells that regulates the immune function.
Studies with in vivo disease models have shown that nicotine-based cholinergic
stimulation prevents the development of rheumatoid arthritis (RA) by inhibiting the
differentiation of CD4+ T cells into Th17 cells, reducing the expression of the RORc
transcription factor, the percentage of IL-17A+ T cells percent, and the concentration
of IL–17A; however it has no influence on the IL-17A+ T cell proliferation..
Furthermore, stimulation of the cholinergic anti-inflammatory pathway could alter the
distribution of Th-17 cells within the collagen‐induced arthritis through the inhibitory
Th-17 cell differentiation (Wu et al., 2018). Moreover, it has been demonstrated that
pretreatment with AChE inhibitors prevented the development of hyperglycemia in
STZ-treated C57BL/6 mice. The increased peripheral cholinergic activity was
associated with a reduction in proinflammatory cytokines (IL-1β, IL-6, and IL-17) and
to a shift in STZ-induced immune response from a predominantly disease-causing IL17-expressing Th17 cells to IFNγ-positive Th1 cells. (George et al., 2016).
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1.5 The inflammatory reflex
The fact that ACh is the major neurotransmitter in the cholinergic nervous system, and
it also participates in the communication between cells in the immune system,
suggested that ACh may participate in the interactions between the nervous and
immune systems. Furthermore, immune cells, as discussed, express muscarinic and
nicotinic receptors and the vagus nerve (a major parasympathetic nerve) innervates
many organs including lymphoid tissues. It was in 2000 when K. Tracy’s group
demonstrated that the interaction between the immune and nervous systems is essential
for the modulation of the inflammatory response (Borovikova et al., 2000). Initially,
it was assumed that cholinergic stimulation of macrophages in the spleen was direct
via the vagus nerve and mediated by the α7 AChR for which this pathway was named
“cholinergic anti-inflammatory pathway” (Borovikova et al., 2000; Wang et al., 2003).
Further studies showed that the vagus nerve does not innervate directly the spleen,
rather it innervates the celiac ganglion and stimulates the adrenergic splenic pathway,
which relays stimuli through splenic T cells to the splenic macrophages (Rosas-Ballina
et al., 2008). The connection between the nervous system and the immune system was
then well stablished. Therefore, both branches (cholinergic and adrenergic) of the
autonomous nervous system regulate immune responses by what is called the
“inflammatory reflex”. The inflammatory reflex as shown in Figure 2 is able to boost
the ability of afferent action in the periphery by the existence of endogenous and
exogenous molecular products, which transmit the signal to the brain in the central
nervous system (Pavlov, Wang, Czura, Friedman, & Tracey, 2003). The vagus nerve
then transmit an efferent action potential and release ACh in the celiac ganglion. ACh
binds to the α7 nAChR on the adrenergic splenic nerve that releases the
neurotransmitter noradrenaline in the spleen, which binds to β2-adrenergic receptors
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expressed in CD3+CD4+CD25- T cells (Vida et al., 2011) but only a particular subset
of these cells (CD4+CD44hiCD62Llo) will produce ACh in response to adrenergic
stimulation (Peña et al., 2011; Rosas-Ballina et al., 2011). Afterwards, ACh will
interact with α7 nAChR expressed on macrophages resulting in the suppression of
proinflammatory cytokines (like IL-1 and TNF-α) production thus reducing the
inflammatory responses (Borovikova et al., 2000). A shock model of the splanchnic
artery occlusion (SAO) is characterized by systemic inflammatory reactions caused by
increased TNF-α production and the accumulation of neutrophils in different organs,
in particular lungs and liver, and ultimately organ failure. In an animal model of SAO,
vagus nerve stimulation reduced NF-b activation and decreased the mRNA TNF-α
expression leading to a reduction of TNF-α levels in the circulation. Vagus nerve
stimulation also reduced the accumulation of leukocytes in ileum and lungs probably
due to the decrease in TNF-α which reduced the inflammatory cascade. These
modulations by vagus nerve stimulation enhanced the time and rate of mice survival
that led to a protective impact (Altavilla et al., 2006). In animal models of
inflammatory diseases such acute kidney injury, obesity and collagen-induced
arthritis, cholinergic stimulation using nAChR agonists lead to a decrease in the
inflammatory reactions (Chatterjee et al., 2012; Van Maanen et al., 2009).
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Figure 2: The inflammatory reflex. Prototypical immune regulation circuit reflex
consists of afferent, efferent vagus nerve signals that react to diseases and wounds in
molecular substances, such as cytokines, eicosanoides, DAMPs and PAMPs. The
induction of neurons in the spleen results in norepinephrine produced in the vicinity of
T cells which can secrete acetylcholine. Acetylcholine passes the marginal area and
reaches into the red pulp, where it interacts with α7 nAChR expressed on cytokine
producing macrophages. The production and release of TNF, IL-1, IL-18, HMGB1,
and other cytokines are inhibited with α7 nAChR signal transduction (Andersson &
Tracey, 2012).

Using live infectious models, some studies have shown that the decreased in
production of pro-inflammatory cytokines and cell recruitment to the site of infection
induced by cholinergic stimulation, affected the bacteria clearance and, therefore the
animal survival rate which was lower than in the control non-stimulated group (Van
Westerloo et al., 2005). This impact was overturned in α7 nAChR deficient mice where
the recruitment of neutrophils was faster (Giebelen et al., 2008). On the other hand,
using a murine model of endotoxemia and sepsis, cholinergic stimulation and
activation of the inflammatory reflex through selective α7 nAChR agonist, vagus nerve
stimulation and other ACh imitating agents was able to improve the survival of
infected animals (Pavlov, 2008). Moreover, cholinergic stimulation induced a
reduction in pro-inflammatory cytokines such TNF-α, protecting the vital organs from
TNFa-induced tissue injury during sepsis, and preventing multiple organ failure
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(Borovikova et al., 2000; Van Westerloo et al., 2005). Furthermore, pretreatment with
an specific AChE inhibitor, paraoxon, enhanced the survival of mice infected with
lethal S. Typhimurium (Al-Barazie et al., 2018; Fernandez‐Cabezudo et al., 2010).
Furthermore, the activation of the M3 mAChR enhanced Th1 and Th2 adaptive
immune reactions in Salmonella infection by enhancing IFN-γ and IL-13 production
respectively, which result in protection (Darby et al., 2015).
1.6 Immuno-physiology of the gastrointestinal tract
Digestion and absorption of distinct nutrients required for survival are the primary
roles of the gastrointestinal system (GIT). GIT is also considered the primary defense
against microorganisms and food antigens that are orally ingested. The defense
mechanisms include saliva, gastric acidity, intestinal mucosa, peristaltic movement,
epithelial cell membrane and intracellular junctional complexes that inhibit antigens
translocation and insure their elimination (Singh et al., 2009).
The small intestine is human body's longest organ, and the most significant component
of digestion. The adult small intestine is about 16 feet and has 1-inch diameter, but due
to the presence of villi and microvilli its surface of absorption is 500 times higher
(Santaolalla, Fukata, & Abreu, 2011). There are three separate components in the small
intestine: duodenum, jejunum and ileum where nutrient intake takes place.
The gut is continually exposed to a variety of dietary and environmental pathogenic
and non-pathogenic antigens. To maintain gut homeostasis specifically in intestine, the
body has developed various mechanisms including the mucosal and epithelial barrier,
intestinal innate and adaptive system and pro-inflammatory signaling pathways (Feng
& Elson, 2011). These mechanisms control the gut flora and the pathogenic population
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that drives inflammation (Geremia, Biancheri, Allan, Corazza, & Di Sabatino, 2014;
Konrad, Cong, Duck, Borlaza, & Elson, 2006).
In the intestinal mucosa, the first layer of protection against pathogens is the epithelium
facing the intestinal tract's luminous surface. It consists of several types of cells that
originate from progenitor stem cells: absorptive enterocytes, goblet cells which
produce mucus, enteroendocrine hormone-producing cells, Paneth cells that produce
anti-microbial peptides, and M cells, specialized in antigen testing (Figure 3). Below
the epithelium is the lamina propria, which contains immunocompetent cells such T,
B cells, macrophages and DC (Niess et al., 2005; Rescigno, 2006).

Figure 3: Components of the intestinal epithelial barrier in small intestine. The
intestinal epithelium in the small intestine consists of a single layer of enterocytes
interspersed by specialized cells. Goblet cells between the epithelial cells responsible
to produce mucus. Paneth cells in the crypt release antimicrobial peptides (AMP).
Antigen testing across the intestinal barrier is mediated by microfold (M) cells. Below
the epithelium is the lamina propria, which contains immunocompetent cells such T
and B cells, and dendritic cells (DC) (Bossche, 2017).
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The innate immune response in the mucosa is mainly driven by macrophages and
dendritic cells. Dendritic cells are located below the intestinal epithelium but the
cytoplasmic extensions of these cells are interdigitated between the epithelial cells in
order to face the luminal contents and present foreign components to T cells in the
lamina propria and underlying lymphoid follicles (Niess et al., 2005; Rescigno, 2006).
T and B cells are the components of the adaptive immune system in the LP and Peyer's
patches. However, in the intestinal environment it is not worth separating adaptive and
innate immune responses, since there is an intimate relationship to the microbiota
present in gut (Santaolalla et al., 2011).
An important component of the mucosal barrier is the mucous layer produced by
goblet cells. This mucous layer constitutes a perfect niche for microbiota to live
protected from being washed out and, at the same time serves as a nutrient for some
members of the microbiota like saccharolytic bacteria (Garrett, Gordon, & Glimcher,
2010). The intestinal mucins produced by the goblet cells are arranged in a bilayer
composed of a firm inner layer free from bacteria and a looser external layer
(Johansson et al., 2008). The most abundant type of intestinal mucin is MUC2 and, in
fact, mice with missense MUC2 mutations had been shown to develop intestinal
chronic inflammation similar to ulcerative colitis (UC) in humans. Moreover, defective
mutant MUC2 multimers caused stress conditions in the endoplasmic reticulum (ER)
and enhanced the unfolded protein response (Heazlewood et al., 2008). Finally, in
human UC, the intestine frequently shows a loss of goblet cells and therefore, mucus
depletion (Gersemann et al., 2009).
Paneth cells present in the intestinal crypts, produce different antimicrobial molecules
such as zinc, lysozyme, and defensins that play a major role in a host defense against
antigens. The release of antimicrobial molecules from Paneth cells is induced by
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microbiota through cell-autonomous MyD88-dependent activation of toll-like
receptors (TLRs), and it helps in protecting the epithelial barrier from breaking by
commensal and pathogenic bacteria (Vaishnava, Behrendt, Ismail, Eckmann, &
Hooper, 2008). Several studies have shown the significance of Paneth cells for the
intestinal homeostasis (Kaser & Blumberg, 2009).
1.6.1 Gut-associated lymphoid tissue (GALT)
Gut-associated lymphoid tissue (GALT) is a component of the mucosa-associated
lymphoid tissue (MALT) that protect the body from pathogen invasion in the gut.
GALT includes Peyer’s patches, mesenteric lymph nodes and different scattered
lymphocytes present in the intestinal lamina propria and intestinal epithelium
(Forchielli & Walker, 2005).
1.6.1.1 Peyer’s patches
Peyer’s patches are aggregated lymphoid nodules, are small organized lymphatic
tissue found in the small intestine, specially in the ileum region. About 100 of them
are found in humans and 8-10 in mice. They play an important role in the intestine
where they direct the intestinal bacteria populations and inhibit the growth of
pathogenic bacteria. In general, structurally PPs have three different compartments:
the follicle-associated epithelium (FAE), subepithelial dome (SED) and follicular
region as shown in Figure 4.
•

Few characteristics make FAE different from typical small intestinal villus
epithelium. FAE has a smaller number of goblet cells, and consequently thinner
mucus layer (Ermund, Gustafsson, Hansson, & Keita, 2013), and contains
antigen-sampling microfold cells (M cells), specialized in the absorption and
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transport of lumen antigens (Owen & Jones, 1974). In fact, the cytoplasm of
M cells contains tiny transcytosis endocytic vesicles that allow these cells to
sample the contents of lumen (particular and pathogenic matter) and transport
them to the basolateral membrane throughout the epithelium. FAE is less
permeable to ions and macromolecules due to the high expression of tight
junction proteins (Markov, Falchuk, Kruglova, Radloff, & Amasheh, 2016).
Finally, as opposed to intestinal villus, the basal lamina of follicle-associated
epithelium is more porous compared to intestinal villus (Takeuchi & Gonda,
2004).
•

In the SED area dendritic cells (DCs) are very abundant making up ~10% of
the total PPs population. DCs are able to uptake and process the antigens
transported by M cells and present them to mucosal T and B cells in order to
produce antigen-specific responses.

•

In the follicular area, the most abundant cells are B cells, representing
approximately 60% of the population. T cells are mostly located in the
interfollicular region (IFR) of the PPs and represent around 25% of the
population. 45% of the T cells are CD4+, 35% are CD8+ and 20% are CD4/CD8- T cells (Iwasaki & Kelsall, 2000). Among the T cells, CD4+/CD25+
(10%) cells and CD8+/CD25+ (5%) cells are richer in Peyer's patches than in
the peripheral blood (Jung, Hugot, & Barreau, 2010).
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Figure 4: PPs three different compartments. The follicle-associated epithelium (FAE),
subepithelial dome (SED) and follicular region (Mowat, 2003).

1.6.1.2 The mesenteric lymph nodes (MLNs)
They present in the intestinal mesentery are the primary sites where nutrients and
microbial agents are taken by lymph fluid from the intestinal lamina propria. They
serve as central sites where tolerance to food particles is induced at the same time that
avoid the systemic spread of microorganisms. In each MLN, three areas can be
observed: (a) the cortex with follicles consisting of B cells and dendritic cells, (b)
paracortex that contains large proportion of T-cells and dendritic cells and finally, (c)
the medulla, composed of B cells and T cells (Ramiro-Puig, Perez-Cano, Castellote,
Franch, & Castell, 2008). Antigen presenting cells carry the antigen and transport it
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from the intestinal epithelium to the MLNs to be presented to the naïve T cells in the
paracortex where they initiate the adaptive immune response. Subsequently, the
activated T cells leave the MLNs and migrate to other organs like liver and spleen
(Kobayashi et al., 2004; Ramiro-Puig et al., 2008). B cells in MLN contribute to the
release of secretory IgA in the gut lumen (Yamamoto et al., 2000).
1.6.1.3 The intestinal mucosa
Constituted by the intestinal epithelium, the basement membrane and the lamina
propria (LP). LP is a thin layer of loose connective tissue lying below the epithelium,
that contains a population of very different cells like fibroblasts, lymphocytes, plasma
cells, macrophages, DCs, eosinophilic leukocytes, and mast cells. The epithelium
contains IELs (intraepithelial lymphocytes) in the interepithelial space between the
tight junctions and the basal membrane of the gut epithelium (Lefrançois & Lycke,
1996).
The lymphocytes in this intestinal compartment are T cells, both CD8+ and CD4+,
which do not need antigen presentation, instead they interact directly with the antigen
and produce cytokines causing the killing of infected target cells (Lefrançois & Lycke,
1996), (Hopper et al., 2006). Intraepithelial CD8+ T lymphocytes can be divided into
two major groups, based on expression of either an αβ T-cell receptor (TCR) or a γδ
TCR. The percentage of both groups are almost equal in mice, while in humans the
majority of IELs express αβ TCR with only 15% γδ TCR+ (Turvey & Broide, 2010).
Many important immune functions have been related to γδTCR+ T cells, including
rapid production of cytokines that may regulate pathogen clearance, inflammation, and
intestinal homeostasis. γδTCR+ T cells stimulate inflammation by the production of
IL-17 or IFN-γ that induce the lysis of infected cells through lytic granules or death
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receptors (Hamada et al., 2008; Martin, Hirota, Cua, Stockinger, & Veldhoen, 2009),
at the same time, they inhibit inflammation by the production of IL-10 (Rhodes,
Andrew, Newton, Tramonti, & Carding, 2008) and produce keratinocyte growth factor
(KGF) that regulates epithelial cell integrity and healing. It has been shown that
absence of γδ TCR+ T cells causes defects in the tight junction formation resulting in
increased intestinal permeability, and translocation of pathogens across the epithelial
barrier in infection models (Dalton et al., 2006).
Finally, the intestinal mucosa contains the innate lymphoid cells (ILCs), a recently
described family of lymphocytes with phenotypes and functions that are similar to T
cells. However, ILCs are present mostly in non-lymphoid tissue and lack the
expression of lineage markers and antigen receptors and do not undergo clonal
selection and expansion upon stimulation. Instead, they respond directly to various
stimuli and produce cytokines that aid in the initiation of immune responses. ILCs
develop from a common lymphoid progenitor and their differentiation depends on the
expression of specific transcription factors that will suppress the generation of B and
T cells to direct the production of the different types of ILCs. ILCs have been classified
into three groups (ILC1, ILC2 and ILC3) depending on the transcription factor
expressed and cytokines produced as shown in Figure 5 (Eberl, Colonna, Di Santo, &
McKenzie, 2015). ILC1s, ILC2s, and ILC3s are the “innate” equivalents of Th1, Th2,
and Th17 CD4+ effector cells, respectively, based on the type of cytokine produced
(Eberl et al., 2015): ILC1 and Th1 cells can produce IFN and TNF; ILC2, like Th2
cells, can produce IL-4 and IL-13; ILC3, like Th17 cells, can produce IL-17 and IL22. Moreover, similar transcription factors are required for the differentiation and
development of Th cells and ILCs: T-bet for Th1 and ILC1, GATA-3 for Th2 and

Figure 5: Activation and functions of ILCs. The tissue signals expand and activate ILC1s, ILC2s,
and ILC3s depending on specific transcription factor. ILC directly response to the stimuli and
produce the cytokines that develop the immune response (Eberl et al., 2015).
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ILC2 and RORrt for Th17 and ILC3 (Artis & Spits, 2015; Zhong & Zhu, 2015; Zook
& Kee, 2016).
1.7 Effect of the cholinergic system on the GI tract
Several studies showed the effect of cholinergic system and its components on various
intestinal activities like motility, secretions and material absorption. Moreover, the
cholinergic system is able to modulate the innate immune response in different
intestinal diseases like inflammatory bowel disease (IBD). During surgical
manipulation of the intestine, macrophages are activated, inducing the production of
inflammatory cytokines, upregulation of adhesion molecules, and invasion of
neutrophils and other leukocytes. To avoid these consequences, Mattioli and his
colleagues showed that electrical vagus nerve stimulation (VNS) for 5 minutes before
intestinal manipulation avoided macrophages activation and preserved GI motor
function. However, using the intestinal muscularis inflammation model, splenectomy
did not have any effect on the anti-inflammatory response, indicating that VNS exerts
a direct effect over the GI immune system preventing postoperative ileus (Matteoli et
al., 2014)
In other studies where colitis was induced in rats by TNBS (2,4,6-trinitrobenzene
sulfonic acid) administration, pretreatment with AChE inhibitors (neostigmine and
physostigmine) decreased colitis severity (Meregnani et al., 2011; Miceli & Jacobson,
2003). Moreover, using the same TNBS model in mice, subdiaphragmatic bilateral
vagotomy or removal of the splenic nerve caused an increase in disease severity of
colitis (Munyaka et al., 2014; O'Mahony, van der Kleij, Bienenstock, Shanahan, &
O'Mahony, 2009). Other studies have shown that defects in nAChRs on immune cells
could lead to the development of IBD. However, many other factors such as smoking
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could affect the development and progression of IBD (Cosnes, 2008; Lunney & Leong,
2012) . Moreover, AChE microRNA-132 (miR-132) which function is to regulate the
expression levels of other genes, has been proposed to have some potential in
decreasing AChE in immune cells and, therefore, to attenuate inflammation (Shaked
et al., 2009).
Using an infectious model, it has been demonstrated that AChE inhibition and,
therefore, activation of the cholinergic pathway is able to induce a protection against
virulent oral enteric pathogens. This protection was correlated with massive
degranulation of two types of intestinal secretory cells, goblet and Paneth cells, which
enhanced the gastrointestinal barrier defense mechanisms (Al-Barazie et al., 2018). All
these studies highlight the anti-inflammatory effect that cholinergic activation exerts
on the intestine.
1.8 Salmonella infection
Salmonella spp. are Gram-negative flagellated bacteria that can cause food and waterborne gastroenteritis and typhoid fever in humans (Mathur et al., 2012). Salmonella
enterica serovar Typhimurium causes a systemic infection in mice that resembles
typhoid fever caused by S. enterica serovar Typhi in humans. All Salmonella species
are facultative anaerobic intracellular pathogens (Jantsch, Chikkaballi, & Hensel,
2011) that can invade several types of cells like epithelial cells, M cells, macrophages
and dendritic cells (LaRock, Chaudhary, & Miller, 2015).
In order to infect the host, Salmonella display a variety of mechanism to cross the
gastrointestinal epithelial barrier. First, Salmonella induce membrane ruffling in M
cells to gain access and infect M cells present in the intestinal epithelium located above
the Peyer patches. After infection, M cells die and Salmonella is translocated to the
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Peyer’s Patches (PP) (Jones, Ghori, & Falkow, 1994). The subepithelial DCs in the
PPs take up Salmonella following M cell invasion (Hopkins, Niedergang, CorthesyTheulaz, & Kraehenbuhl, 2000). After exposure to antigen (Salmonella), immature
DCs become mature DC and present the microbial peptide to naïve B and T-cells in
the mesenteric lymph nodes (Murphy, Travers, & Walport, 2012). Salmonella can also
directly interact with IECs to get internalized (Finlay & Falkow, 1990) and translocate
to the intestinal lamina propria (Chieppa, Rescigno, Huang, & Germain, 2006; Niess
et al., 2005).
Intestinal epithelial cells can also directly recognize invading pathogens through the
interaction between pathogen-associated molecular patterns (PAMPs) present in
bacteria and Toll-like receptors in the epithelial cells. Each type of TLRs recognizes a
unique PAMP. It is TLR4 that recognizes the lipopolysaccharide (LPS) from Gramnegative bacterial cell walls (Hallstrom & McCormick, 2011). Upon PAMP
recognition the immune response is initiated by activation of the NFB that leads to
the production of proinflammatory cytokines and chemokines. Secretion of IL-8
induces recruitment of neutrophils while CCL20 chemokine production attracts
immature dendritic cells (Patel & McCormick, 2014). Salmonella can also interact
with TLRs in macrophage and induce the production of different cytokines such as IL1, IL-6, and IL-23 which are important for Th17 cell differentiation and recruitment
of neutrophils (Godinez et al., 2009; Murphy et al., 2012). Activated macrophages can
also produce IL-18 and IL-12 that are involved in the production of IFN cytokine
(Murphy et al., 2012).
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1.9 Acetyl cholinesterase inhibitors
Several diseases that result from cognitive shortages in elderly people are the reasons
behind the discovery of cholinesterase inhibitors. Since ACh has been demonstrated
to be involved in cognitive processes, the idea of increasing acetylcholine levels by
inhibiting the cholinesterase enzyme to restore cognitive loss “cholinergic hypothesis”
has got much attention and interest (Kandiah et al., 2017; Martorana, Esposito, &
Koch, 2010).
Degeneration of cholinergic neurons in the brain causes a reduction in the levels of
acetylcholine and cholinergic function, which lead to diseases such as Alzheimer’s
disease (AD). Most AChE inhibitors bind to the active site of the AChE enzyme and
inhibit the binding of ACh, reducing the degradation of synaptic acetylcholine,
improving brain acetylcholine levels in a dose-dependent manner and enhancing
cholinergic transmission in patients with Alzheimer’s and other dementias. AChE
inhibitors have some side effects such as, constriction of the pupils in the eyes,
vasodilation, increased secretion of sweat, saliva and tears, slow heart rate, mucus
secretion in the respiratory tract and constriction of the airways (Kandiah et al., 2017).
AChE inhibitors can be divided into two groups: reversible and irreversible. The
reversible inhibitors, competitive or non-competitive, are used as therapeutic agents.
Reversible acetylcholinesterase inhibitors have temporary effects on the enzyme
maintaining the functionality of the active site. Once the reversible inhibitors are
removed, the acetylcholinesterase enzyme recover its activity. On the other hand,
irreversible AChE inhibitors used at high dose have toxic effect through non-reversible
phosphorylation of esterases in the central nervous system. The acute toxic effects are
related to irreversible inactivation of AChE (Colovic, Krstic, Lazarevic-Pasti,
Bondzic, & Vasic, 2013). The typical symptoms of acute poisoning are agitation,
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muscle weakness, muscle fasciculations, miosis, hypersalivation and sweating. Severe
poisonings may cause respiratory failure, unconsciousness, confusion, convulsions
and/or death (Costa, 2006; World-Health-Organization, 1986). Most of the
organophosphorus used as pesticides are irreversible acetylcholinesterase inhibitors.
Rivastigmine ((S)-3-[1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate) is
a pseudo-irreversible, carbamate-type, brain-selective, dual acetyl- and butyrylcholinesterase (BuChE) inhibitor (Kandiah et al., 2017). Rivastigmine has been
approved in 60 countries including all members of the European Union and the USA
(Birks, Chong, & Grimley Evans, 2015) for the treatment of Alzheimer’s and other
dementias as it reduces the degradation of synaptic acetylcholine and, therefore,
increases the levels of ACh available for synaptic transmission which causes
symptomatic therapeutic effects. The pharmacokinetic profile showed that compared
with the oral formulation, rivastigmine transdermal patch provides smoother and
continuous as well as controlled drug delivery over 24 h, thereby resulting in fewer
side effects (Kandiah et al., 2017).
Previous studies showed that chronic administration of a specific and irreversible
inhibitor of AChE, paraoxon, improved the survival of mice following an oral infection
with virulent Salmonella bacteria. This was mediated by cholinergic pathwaydependent enhancement of anti-microbial immune defenses acting at the level of the
gastrointestinal mucosal surfaces (Al-Barazie et al., 2018). However, paraoxon is an
organophosphorus compound unsuited for human use, therefore, the study aimed to
test the efficacy of rivastigmine, an FDA-approved inhibitor of AChE, on mucosal
defenses against Salmonella infection. Results show that rivastigmine treatment,
previous to an oral infection with a virulent strain of Salmonella increased the survival
of mice orally infected and delayed the translocation of pathogenic bacteria to the
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systemic sites. Results showed that rivastigmine induced the degranulation of two
specialized intestinal secretory cells involved in innate immunity, goblet cells and
Paneth cells, and increased the thickness of the mucin layer in colon tissue.
Immunohistochemical study of the ileum revealed that rivastigmine treatment resulted
in few changes in the lymphoid population in the epithelium and lamina propria (LP).
Further, evidence provided by flowcytometric phenotypic analysis that rivastigmine
does not induce recruitment of T cells to the intestinal mucosa as effectively as
paraoxon, suggesting the essential role that these cells play on the protection against
an oral infection. The findings demonstrate an effect of cholinergic stimulation on
immune cells that is correlated with the type of AChE inhibitor and, therefore, with
the availability of ACh to bind their receptors.
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Chapter 2: Hypothesis
Cholinergic stimulation using paraoxon, an irreversible AChE inhibitor, enhanced
innate immunity at the level of intestinal epithelium by increasing goblet and Paneth
degranulation and, therefore, inducing mucus and antimicrobial peptides secretion,
respectively. Paraoxon treatment was also able to enhance protection against oral
infection with virulent Salmonella. Depending on that, the first hypothesis of this study
is cholinergic stimulation by rivastigmine, a more physiologically relevant AChE
inhibitor, will also be able to exert the same effect as paraoxon. Also given the fact
that immune cells express ACh receptors, so the second study hypothesis is cholinergic
stimulation could also modulate the immune population present in the intestinal
mucosa and contribute to the enhanced defense against bacterial infection as shown in
Figure 6.
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A

Figure 6: Project hypothesis. Schematic diagram representing the effect of AChE
inhibition using paraoxon (A) or rivastigmine (B) on goblet and Paneth cells in the
intestinal epithelium, which enhances protection against Salmonella. The hypothesis
is that AChE inhibition also exerts an effect on professional immune cells in the
intestinal mucosa.
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B

Figure 6: Project hypothesis. Schematic diagram representing the effect of AChE
inhibition using paraoxon (A) or rivastigmine (B) on goblet and Paneth cells in the
intestinal epithelium, which enhances protection against Salmonella. The hypothesis
is that AChE inhibition also exerts an effect on professional immune cells in the
intestinal mucosa (Continued).
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Chapter 3: Aim and Objectives of the Study
Previously, it has been demonstrated that cholinergic stimulation using paraoxon, a
specific and irreversible acetylcholinesterase (AChE) inhibitor, enhanced survival in
mice following an oral infection with virulent Salmonella enterica serovar
Typhimurium (S. Typhimurium). However, paraoxon is an organophosphorus
compound unsuited for human use. This study aimed to investigate the effectiveness
of rivastigmine, an FDA-approved inhibitor of AChE, on mucosal defenses against
Salmonella infections.
The specific objectives were to:
•

Characterize the effect of AChE inhibition by rivastigmine on mouse survival
following oral infection with virulent S. typhimurium.

•

Determine the effect of rivastigmine treatment on the bacterial load in the feces,
intestinal content and organ homogenates at an early time point after infection.

•

Investigate by electron microscopy the ultrastructural changes in intestinal
epithelial cells, specially Paneth cells and goblet cells, following rivastigmine
treatment.

•

Investigate by light microscopy the effect of rivastigmine treatment on the
secretion of mucin and lysozyme by goblet and Paneth cells, respectively.

•

Investigate by immunohistochemistry the effect of rivastigmine on the
distribution of the different immune cell populations in the intestinal mucosa.
Where possible, quantification of labeled cells will be performed.

•

Evaluate by flow cytometry the effect of AChE inhibition by paraoxon or
rivastigmine on the cellular phenotype and activation status of lymphoid and
myeloid cell populations present in the intestinal epithelium and lamina propria.
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Chapter 4: Materials and Methods
4.1 Materials
All materials, standard solutions or antibodies used to conduct the experiment are
mentioned below.
4.1.1 Standard solutions
Different solutions used for the different techniques. Table 2 shows the preparation of
each solution.
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Table 2: Standard solutions
Solution
0.1 mol/ml phos
phate buffer

10 mM DTNB
6 mM ethoprorazine
Transformation buffer

10x PBS

Staining buffer for flow
cytometric analysis
HBSS

Retrieval solution for
immunocytochemistry
Blocking buffer (BSA) for
immunocytochemistry
Pre-digestion solution for
intestinal lymphocyte
isolation
Enzyme mix mixture for
gentleMACS
Carnoy’s fixative
10% Formalin for fixation
HBSS without
calcium/magnesium
(HBSS w/o)

Preparation
• Solution 1: 17.8 g of Na2HPO4.2H2O in
1L distilled water
• Solution 2: 2.27 g of KH2PO4 in 200 ml
distilled water
To adjust the pH, solution 2 was added,
gradually, to solution 1 until pH became 7.4,
then, it was filtered and stored at 4°C.
396.3 mg DTNB in 100 ml phosphate
buffer. Stored at -20°C.
20.94 mg in 10 ml of 12 mmol/L HCl.
Stored at -20°C.
200 mg potassium ferricyanide, 50 mg
potassium cyanide, 1g sodium bicarbonate
and 500 µl 100% Triton X-100 in 1L
distilled water
87.66 g NaCl, 2.56 g NaH2PO4.H2O and
11.94 g Na2HPO4 dissolved in 1 L of
distilled water.
1 ml fetal calf serum and 0.1 g NaN3 was
dissolved in 100 ml PBS.
0.4 g KCl, 0.09 g Na2HPO4.7H2O, 0.06 g
KH2PO4, 0.35 g NaHCO3, 0.14 g CaCl2, 0.1
g MgCl2.6H2O, 0.1 g MgSO4.7H2O, 8 g
NaCl and 1 g D-glucose in 1 L distilled
water, pH adjusted to 7.4 and stored at 4°C.
1.21 g Tris base, 0.37 g EDTA with 1000 ml
water, pH adjusted to 9.
1 g albumin from bovine serum with 100 ml
PBS with tween.
15 mM EDTA, 5% FBS, 100 mM DTT and
HBSS (w/o)
100 µL of Enzyme D + 50 µL of Enzyme R
+ 12.5 µL of Enzyme A into a gentleMACS
C Tube containing 2.35 ml of pre-heated
digestion solution.
60 ml of methanol, 30 ml of chloroform and
10 ml of acetic acid.
100 ml 37% formaldehyde in 900 ml PBS.
0.4 g KCl, 0.09 g Na2HPO4.7H2O, 0.06 g
KH2PO4, 0.35 g NaHCO3, 8 g NaCl and 1 g
D-glucose, 10 ml of 1 M HEPES in 1 L
distilled water, pH adjusted to 7.4 and stored
at 4°C.
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4.1.2 List of materials used and suppliers
All chemicals used in different techniques are shown in Table 3.

Table 3: List of materials used and suppliers
Chemicals

Company

Catalog #

Paraoxon ethyl

Sigma

36186

Rivastigmine

Sigma

4617

Na2HPO4.2H2O

Panreac

131679.1210

NaCl

Sigma

102H3660

NaN3

BDH

UN No /687

D-glucose

Sigma

G-5767

NaHCO3

Gibco-BRL

11810-074

Lead citrate

Agar scientific

R1210

uranyl Acetate

Agar scientific

R1260

Glutaraldehyde

Agar scientific

R1011

Agar 100 epoxy
Dodecenyl Succinic
Anhydride
Methyl Nadic Anhydride

Agar scientific

R1043

Agar scientific

R1051

Agar scientific

R1081

2,4,6 Tri (dimethylaminoethyl)

Agar scientific

R1065

Probylene Oxide

Agar scientific

00236

EM stain 336

Agar scientific

AGG1260D

Tetramethylbenzidine TMB

BD

51-2607 KC

Toloudine blue

Agar scientific

R1727

Osmium tetroxide

Agar scientific

R1024

Mesh cover grid

Agar scientific

G2100C

Agar 100 Resim

Agar scientific

R1043
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4.1.3 List of antibodies used for FACS staining
All antibodies used for flowcytometry experiments are shown in Table 4.

Table 4: List of antibodies used for FACS staining
Antibody

Host

Conjugate

Catalog # Company

Dilution

CD45

Rat

103112

Biolegend

2.5 g/ml

CD45

Rat

APC
Alexa Fluor
700 (APCR700)

103127

Biolegend

2.5 g/ml

CD11b

Rat

APC-Cy7

101226

Biolegend

2.5 g/ml

CD11b

Rat

Alexa Fluor
488

101217

Biolegend

2.5 g/ml

CD16/CD32

Rat

-

101302

Biolegend

10 g/ml

F4/80

Rat

PE

123109

Biolegend

0.75 g/ml

CD11c

Armenian
Hamster FITC
IgG

117306

Biolegend

2.5 g/ml

Ly6G

Rat

BV-605

127639

Biolegend

2.5 g/ml

Ly6c

Rat

PE

128008

Biolegend

0.75 g/ml

CD8β

Rat

FITC

140404

Biolegend

1:200

CD4

Rat

PerCP

100432

Biolegend

2.5 g/ml

CD4

Rat

APC

100412

Biolegend

2.5 g/ml

7-AAD

-

PerCP

420404

Biolegend

1:100

CD3

Armenian
Hamster FITC
IgG

100306

Biolegend

5 g/ml

CD3

Rat

BV-785

100232

Biolegend

2.5 g/ml

CD19

Rat

BV-650

115541

Biolegend

2.5 g/ml

BV-510

423101

Biolegend

1:200

BV-785

107645

Biolegend

2.5 g/ml

APC-Cy7

107628

Biolegend

2.5 g/ml

APC-Cy7

100714

Biolegend

5 g/ml

Zombie Aqua
Fixable
Viability Kit
I-A/IRat
E(MHCII)
I-A/IRat
E(MHCII)
CD8α

Rat
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4.1.4 List of antibodies used for immunocytochemistry
Table 5 shows the list of antibodies used for immunocytochemistry to stain section of
intestine.

Table 5: List of antibodies used for immunocytochemistry
Antibody
CD8
CD4

Host
Reactivity
rabbit Anti-mouse
rabbit Anti-mouse

F4/80

rat

IFN-

rabbit Anti-mouse

Ki67

rat

Lysozyme
Mucin
Secondary
antibody (FITC)
Signa lstain
boost IHC
Streptavidin
FITC
Biotin

rabbit Anti-mouse
rabbit Anti-mouse
goat
Anti-rabbit

Anti-mouse

Anti-mouse

Anti-rabbit

Goat

Anti-rat

Catalog #
Company
Ab183685 Abcam
Ab203035 Abcam
BMA
T-2006
Biomedicals
Ab231036 Abcam

Dilution
1:2000
1:1000
1-100

11-4317

1:200
Pre
Abcam
diluted
Dako
1:300
Santa Cruz
1:100
Jackson Immune 1:100
Research
Cell signaling
Pre
diluted
e-bioscience
1:100

3030-08

SouthernBiotech 1:200

ab21700
A0099
Sc 15334
111-095003
8114S

4.1.5 Mice
BALB/c mice purchased from Harlan Olac (Bicester, UK), were bred in the animal
facility at the College of Medicine and Health Science, United Arab Emirates
University (UAEU). Mice were housed in plastic cages with a controlled light and dark
cycle of 12 hours each at 24-26°C and received rodent chow and water ad libitum. All
animals for this study were male and used at 8-12 weeks of age, weighing 20-25 g. All
studies involving animals were carried out in accordance with, and after approval of
the animal research ethics committee of the College of Medicine and Health Science,
UAEU (Protocol no.AE/06/81).

40
4.2 Methods
All methodology used to conduct experiments will be listed below.
4.2.1 Paraoxon preparation
Paraoxon ethyl (Sigma Chemicals Co., St Louis, MO) solution was prepared at a
concentration of 10 mmol/L in anhydrous acetone, and further diluted in 1x PBS to a
stock solution of 1 mmol/L. Working solution with a final concentration of 80 nmol/ml
was also prepared in 1x PBS. Each mouse received daily injection of 40 nmol/0.5 ml
of paraoxon (equivalent to 0.44 mg/kg of body weight) by intraperitoneal (i.p.)
injection. Control animals received an equivalent volume of 1x PBS (0.5 ml).
Injections were given daily for 5 consecutive days, followed by a 2-day break, and this
cycle was repeated for a total of 3 weeks.
4.2.2 Rivastigmine preparation
50 mg/ml of Rivastigmine (Sigma Chemicals Co., St Louis, MO) stock solution was
prepared in DMSO. Working solution was prepared in 1x PBS to a final concentration
of 17.7 µg/µl. Each mouse received daily subcutaneous injection of 200 μl of
Rivastigmine (equivalent to 2 mg/kg). Control animals received an equivalent volume
of 1x PBS (200 μl). All injections were given subcutaneous daily for 5 days, followed
by a 2-day rest, and this cycle was repeated for a total of 3 weeks.
4.2.3 Experimental protocol
Male BALB/c mice with matched age and weight were randomly divided into two
groups. First group received daily injection of PBS and served as control. Second
group received daily injection of 40 nmol of paraoxon or 2 mg/kg of rivastigmine.
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Mice were weighed weekly and blood collected and analyzed for acetyl cholinesterase
(AChE) activity (from only paraoxon-treated mice). At the end of the third week of
treatments, animals were either sacrificed or infected with a virulent strain of S.
Typhimurium (SL1344) and sacrificed at indicated time points. In other experiments,
infected animals were followed for survival.
4.2.4 Red blood cells AChE activity
20 µl of venous blood was collected from the tail, diluted in 2 ml of 0.1 M phosphate
buffer, and stored at -20°C until analyzed. After thawing, 1 ml of the sample was
incubated with 2 ml of phosphate buffer, 100 µl of 10 mM DTNB (5,5’-dithiobis-2nitrobenzoic acid) and 10 µl of 6 mM ethoprorazine for 20 minutes in a water bath set
at 37οC. Then, 50 µl of the substrate, 28.4 mmol/L acetylthiocholine, was added
immediately before measuring the absorbance. The change in the absorbance of the
DTNB was measured at 436 nm using Du-70 spectrophotometer (Beckman coulter
Inc. Pasadena, CA, USA). To measure the total hemoglobin (Hb) content, 1 ml of the
blood sample was incubated with 1 ml of transformation buffer for 10 minutes at room
temperature. Then absorption at 546 nm was read against water blank. AChE activity
was calculated using the absorbance coefficient of TNB- at 436 nm (ε =10.6 mM-1 cm1

). Values were normalized to the Hb content (determined as cyanmethemoglobin) and

expressed as mU/µM/HB (116). All enzyme activity was expressed as percentage of
the baseline activity (100%).
4.2.5 Bacterial strain and preparation
In this study, wild-type virulent strain of Salmonella enterica serovar Typhimurium (S.
Typhimurium) SL1344 was used. To grow the bacteria, Tryptic Soy (TS) agar plates
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used without ampicillin (100 µg/ml). Aliquots from frozen bacteria stock were plated
on TS agar plates. To prepare required dosage, three to five colony-forming units
(CFU) were cultured overnight in 10 ml of Tryptic soy broth (TSB) without ampicillin
(1 µg/ml) and then diluted 1:5 in fresh TSB without ampicillin (1 µg/ml) and incubated
for two hours shaking at 200 rpm and 37οC. On a spectrophotometer at λ=600, 1 ml of
the culture was read to determine bacterial concentration against TSB as blank.
Suitable dilutions of the log- phase bacterial suspension was made in pyrogen-free 1x
PBS to prepare the indicated doses and their verification. To confirmed bacterial dose,
the number of CFUs counted in the plates. For oral inoculation, sodium bicarbonate
(200 µl of 7.5%) was given 4 minutes before oral administration of SL1344 (200 µl)
in order to neutralize the stomach acid. Gavage needles (CADENCE science, Staunton,
VA, USA) were used for the administration of sodium bicarbonate and SL1344.
4.2.6 Determination of bacterial load in target organs and fecal pellets
Fecal pellets were freshly collected from infected animals at day three post infection
before sacrificed, weighed, and homogenized in 0.5-1 ml cold 1x PBS. Then, 100 µl
from the homogenate or appropriate dilution were plated on SS agar plates with
Streptomycin (200 µl/ml). CFUs counts were determined after overnight incubation at
37°C.
Mice were sacrificed at day three post oral infection. Spleen, liver, intestine and
intestinal content were aseptically removed and homogenized in 1 ml cold 1x PBS in
an Ultra-turrax T-25 tissue homogenizer (Janke & Kunkle, Staufenim Breisgau,
Germany). 100 µl aliquot of the homogenate or appropriate dilution were plated on SS
agar with Streptomycin. CFUs counts were determined after overnight incubation at
37°C.
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4.2.7 Flow cytometry
0.5x106 cells/well from isolated cells were incubated in U shaped bottom 96-well plate
(BD) for 30 minutes at 4°C in 50 µl of staining buffer containing anti-CD16/CD32
monoclonal antibody (clone 2.4G2) to block the FcII/III receptors and, therefore,
prevent any non-specific binding of the antibodies. Then, the plate was spun at 900
rpm for 5 minutes at 4°C, decanted, and cells incubated with zombie antibody for
exclusion of non-viable cells. Afterwards, the plate was spun at 900 rpm for 5 minutes
at 4oC, decanted and cells incubated at 4oC for 30 minutes with different combinations
of conjugated monoclonal antibodies (Biolegend or Novus as detailed in above Table
5) in a total volume of 100 µl/well. Then, plates were spun, decanted and cells washed
twice with staining buffer, 200 µl/well. Finally, cells were re-suspended in 200 µl of
staining buffer and either immediately read or fixed overnight by adding 100 µl of 4%
paraformaldehyde. Data were collected on 30,000 cells using BD FACS Celesta (BD
biosciences, Mountain View, CA, USA) and analyzed using BD FACS Diva software
(BD).
4.2.8 Isolation of intestinal epithelial cells and lamina propria
Mice were treated with paraoxon or saline for three weeks. At day three from the last
injection, mice were sacrificed, and whole small intestine excised. Intestinal fecal
content was removed by flushing cold HBSS w/o. Residual fat tissue and Peyer’s
patches were carefully removed. Intestine was, then, weighed (only 1 g of tissue was
used), opened longitudinally and cut into small pieces (0.5-1 cm) to which 20 ml of
pre-digestion solution was added (each sample in a different 50 ml tube) and incubated
in a shaking bath at 37°C for 20 minutes. Afterwards, intestinal tissue was vortexed
for 10 seconds, and passed through a 100 µm-pore strainer. Supernatant was collected
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in 50 ml tube and discarded. Intestine pieces were resuspended again in 20 ml of predigestion solution, incubated, vortexed and passed them again through the strainer.
This time supernatant was collected and kept. The tissue incubation was repeated one
more time and supernatants pulled, centrifuge at 300× g for 10 minutes at room
temperature. Supernatant was then, discarded and pellet containing IELs resuspended
in 5 ml PBS.
Intestinal tissue was further processed to obtain leukocytes from the lamina propria
(LP). Intestine tissue was transferred into gentleMACS C tubes containing the enzyme
mixture and incubated at 37°C under continuous shaking for 30 minutes. Then, C tube
was placed into the gentleMACS dissociator, to homogenate the intestinal tissue for
30 seconds (m_intestine_01 program). Then, tube was spun, and pellet collected.
Afterwards, 5 ml of PBS buffer was added, cell suspension passed through a 100 µm
strainer and placed on a 50 ml tube. Strainer was washed with 10 mL of PBS buffer
and LP cell suspension spun at 300× g for 10 minutes at room temperature, supernatant
discarded, and cells resuspended in 5 ml PBS.
4.2.9 Light microscopy analysis of the ileum
Ileum (the distal part of the intestine) was removed and immediately fixed in 10%
Formalin or in Carnoy’s fixative. After overnight fixation, tissues were placed in
histological cassettes, dehydrated with a series of alcohols, 70% to 95% to 100%,
cleared with xylene and then infiltrated and embedded in paraffin (Sherwood Medical,
St. Louis, Mo, USA). Using Shandon Finesse 325 manual microtome (Thermo
Scientific, Pittsburg, PA, USA), paraffin blocks were trimmed, 5 µm sections prepared
and placed on gelatin coated slides. The process of dehydration was done at room
temperature by immersing the sections in xylene I solution for 5 minutes, xylene II for
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5 minutes, absolute ethanol I for 3 minutes, absolute ethanol II for 3 minutes, 90%
ethanol for 3 minutes, 80% ethanol for 3 minutes and finally 70% ethanol for 3
minutes. Antigen retrieval was performed by placing the tissue slides at 200°C for 10
minutes, and then cooled down for 30 mins on ice. Endogenous peroxidase activity
was blocked using 1.5% H2O2 in PBS. After 3 wash cycles with PBS-T (5 minutes
each), the slides were further blocked with 1% BSA in PBS for 45 minutes followed
by incubation with the required concentration of primary antibodies diluted in BSA.
After overnight incubation, slides were kept for one hour at room temperature, washed
and then, incubated with the appropriate secondary antibodies for 30 minutes. 3 wash
cycles with PBS-T (5 minutes each).
For DAB staining: the peroxidase activity was determined using DAB chromogen
(Dako) for 5-10 minutes followed by wash with distilled water. Sections were then,
stained for 1 minute with hematoxyline and rehydrated. Rehydration was in the
following order: 70% ethanol for 1 minute, 80% ethanol for 1 minute, 90% ethanol for
1 minute, absolute ethanol I for 1 minute, absolute ethanol II for 1 minute, xylene I for
2 minutes and xylene II for 2 minutes. Finally, the sections were mounted with DPX
(Panreac, Spain) and images captured with an Olympus BX51 microscope model VLH100HG (Olympus Corporation, Japan).
For Florescent staining: slides were countered stained with propidium iodide for 30
minutes at 37°C. Then, they were washed with PBS and finally mounted with
florescence mounting medium (Dako).
4.2.10 Electron microscopy analysis of the ileum
Ileum (the distal part of the intestine) was removed and immediately fixed in a mixture
of 2.5% glutaraldehyde and 2% formaldehyde solution (pH= 7.2 in phosphate buffer)
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overnight at 4°C. Samples were rinsed with 0.1 M phosphate buffer, post-fixed in 1%
aqueous osmium tetroxide for 1 hour and then rinsed in distilled water. Then, samples
were dehydrated in ascending series of graded ethanol, infiltrated with Agar100 epoxy,
and finally embedded in the same resin where they polymerized at 65°C for 24 hours.
Blocks were trimmed, semithin (0.5 mm) sections cut in an ultramicrotome Leica EM
UC7 (Leica, Welzlar, Germany) and stained with 1% aqueous toluidine blue on glass
slides. Ultrathin (95-100 nm) sections were prepared on 200 mesh copper grids and
contrasted with 2% uranyl acetate for 40 minutes, and lead citrate for an additional 25
minutes. Grids were then air dried on filter paper and the sections examined and
photographed with TENAI G2 Spirit Transmission Electron Microscope (FEI,
Hillsboro, Oregon, USA).
4.2.11 Statistical analysis
Statistical significance between control and treated groups was analyzed by unpaired
two-tailed Student’s t-test or the log rank (Mantel-Cox) test for Kaplan-Meier
functions (for survival analysis) using GraphPad Prism software (San Diego, CA,
USA). Differences between experimental groups were considered significant when p
values were < 0.05.
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Chapter 5: Results
5.1 Rivastigmine exposure retarded body weight gain
In previous studies where paraoxon used, as irreversible AChE inhibitor, the
effectiveness of the treatment monitored by measuring the activity of the enzyme
AChE in peripheral blood after 24 hours of paraoxon injection. However, in this study
rivastigmine used, a reversible AChE inhibitor and, it is not possible to detect any
changes in the RBC AChE activity after 24 hours of rivastigmine injection. Then, in
order to monitor the efficiency of the rivastigmine treatment, body weight was
followed in all animals during the treatment period. Body weights were recorded just
before starting the treatment with either saline (control) or rivastigmine and considered
these weights as baseline. Once the treatment started, mice were weighed weekly and
the percentage change in body weight calculated. Results showed a gradual increase
of body weights in saline treated animals of 4% after the first week, 7% after the second
week and 10% at the endo of the third week. On the rivastigmine-treated group, mice
showed an increase of only 0.7% in their body weights after the first week of treatment.
The following week (week 2), mice experimented an increase of 2% of their initial
weights. Their body weight after the three weeks treatment increased by only 4%
(Figure 7). The differences in body weight growth between the control and
experimental group at each time point and during the experimental period was
statistically significant confirming the effectiveness of the rivastigmine treatment.
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Figure 7: Retarded growth in rivastigmine-treated mice. Mice were treated with
rivastigmine or saline for three weeks. Weekly change in body weight was calculated
as percentage of the initial weight. Depicted are the mean values ± SD of data pooled
from 3 independent experiments. Asterisks denote statistically significant differences
between the control and experimental groups ***p<0.001.

5.2 Rivastigmine treatment enhanced host survival after a lethal infection with
SL1344
Next, study aimed to test if rivastigmine treatment could also protect mice from a lethal
oral infection, as demonstrated paraoxon treatment did (Al-Barazie et al., 2018). After
three weeks treatment with rivastigmine or saline, mice were inoculated orally with
SL1344, a virulent strain of S. Typhimurium at a lethal dose of 2x104 CFUs/mouse.
Mice were then followed for survival for up to day 30 post-infection as shown in Figure
8. Results show that rivastigmine treatment increased significantly the time of survival
to 23 days (14 days medial survival) after infection compared to the 11 days survival
(medial survival of 9.5) in saline-treated group. However, eventually all animals in
both groups succumbed to the infection.
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Figure 8: Rivastigmine treatment enhanced host survival after a lethal oral infection.
Mice were treated with rivastigmine or saline for three weeks. At the end of the
treatment mice were infected orally with a dose of 2x104 CFUs/mouse of SL1344 and
followed for survival up to 30 days post infection. Depicted are the mean values ± SD
of data pooled from two independent experiments. Asterisks denote statistically
significant differences between the control and experimental groups (***p<0.001).
Chi squared (Mantel-Cox) statistical test was used for this analysis.

5.3 Rivastigmine reduces the initial bacterial translocation and systemic
dissemination of oral Salmonella
After three weeks treatment with saline or rivastigmine, mice were orally infected with
a high dose of virulent Salmonella strain SL1344 (1x105 CFUs/mouse). Mice were,
then, sacrificed at day 3 post-infection, and spleen, liver and intestine aseptically
removed. Fecal pellets were also collected just before sacrifice.
Bacterial load estimation showed higher number of CFUs in the fecal pellet and
intestinal content of rivastigmine-treated mice when compare with saline-treated
control group (Figure 9). However, the opposite was observed in target organs like
spleen and liver where the number of bacteria were higher in the control group than in
the rivastigmine-treated group (Figure 9). These results suggest that rivastigmine
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treatment prevented the translocation and, therefore, the dissemination of bacteria.
Interestingly, no differences between the control and rivastigmine groups were found
in the number of CFUs of the whole intestine (tissue + content). This is probably due
to the fact that in the control group bacteria is not in the content anymore but it is
already in the intestinal tissue after translocation, while in the rivastigmine-treated
group is in the intestinal content but not in the tissue.
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Figure 9: Reduction in the bacterial load in systemic organs of rivastigmine pre-treated
mice after 3 days of oral infection. Mice were treated with saline or rivastigmine for 3
weeks and then infected orally with SL1344. Mice were sacrificed and organs
homogenates aliquots were plated to determine bacterial load. Bacterial loads were
determined as CFUs/mg in intestine, feces, intestinal content, spleen and liver at day
3 post infection as shown in A-B and C. Graph shows mean ± SEM of data from 2
independent experiments.
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Spleens obtained, from saline- and rivastigmine-treated mice, at day 3 post-infection
with high dose of SL1344 were weighted and plotted in Figure 10. Although no
statistically significant difference was found between the spleen size of both groups,
the saline pre-treated group showed an average of 76 mg compared to the 65 mg in the
rivastigmine-treated group. This small splenomegaly correlates with the higher
bacterial load found in the control group.

Figure 10: Spleen weights after 3 days of oral infection. Mice were treated with saline
or rivastigmine for 3 weeks and then infected orally with SL1344. At day 3 postinfection, mice were sacrificed and spleen weight measured. Graph depicts mean ±SD
of data from 3 independent experiments.

5.4 Morphological analysis of the intestinal mucosa revealed an induction of
mucus and lysozyme secretion following rivastigmine administration
Next, study aimed to investigate if rivastigmine treatment induces any changes on the
intestinal mucosa as this is the site where orally administered bacteria will encounter
the first host defense mechanism against infection. More specifically, looked at
morphological changes at the level of the intestinal epithelium that could affect the
translocation of bacteria from the intestinal lumen to the submucosa. Following three

52
weeks of treatment with rivastigmine or saline (control), mice were sacrificed and
small intestine (ileum) collected and prepared for morphological analysis. Within the
intestinal epithelium the focusing were on characterizing, by electron- and light
microscopy, the effect of rivastigmine treatment on the main cells involved in the
mucosal defense against pathogens: goblet cells, Paneth cells and immune cells.
5.4.1 Goblet cells: mucin production
5.4.1.1 Rivastigmine treatment induced degranulation of Paneth cells
Goblet cells are located among the columnar epithelial cells of the intestinal
epithelium. Intestinal goblet cells in saline-treated mice are large and rounded and
showed the presence of an extensive endoplasmic reticulum as well as densely packed
granules located on the apical side of the nucleus (Figures 11A-B). However, intestinal
goblet cells observed in the rivastigmine-treated group appeared depleted granules
with the cellular apical side complete open to the intestinal lumen where granules are
being released (Figures 11C-D). This massive secretion seemed to disrupt the cell
membrane and, often to induce the release of cytoplasmic fragments and cell death.
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Figure 11: Rivastigmine treatment induced degranulation of Paneth cells. Goblet cells
in ileum sections from saline- (A-B) and rivastigmine-treated mice (C-D). Goblet cells
(arrow) in saline treated animals showed large and rounded mucous globules. In
contrast, goblet cells from rivastigmine treated animals presented an active
degranulation of the granules to the intestinal lumen, or complete degranulated cell.
Figure bars indicate 1 m. L: intestinal lumen; N: nucleus; ER: endoplasmic reticulum.

5.4.1.2 Administration of rivastigmine induced the release of mucin to the
intestinal lumen
Goblet cells synthesize several bioactive molecules that are secreted to the intestinal
lumen forming the intestinal mucus layer. The most abundant of these molecules is
mucin. So, also analyzed goblet cells degranulation immunohistochemically using a
specific anti-mucin antibody. As shown in Figures 12A-B, the distal region of the
small intestine (ileum) in saline-treated mice showed rounded positive cells with dense
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staining in their cytoplasm along the intestinal epithelium. On the other hand,
equivalent sections from ileum of rivastigmine-treated mice presented less intense
staining and an opened apical region releasing the mucin to the intestinal lumen
(Figures 12C-D).
Saline
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Figure 12: Administration of rivastigmine induced the release of mucin to the intestinal
lumen. Light confocal micrographs of ileum sections showing immunofluorescence of
mucin-containing (green) goblet cells in (A-B) saline and (C, D) rivastigmine-treated
mice. Original magnification (A-C) 200x and (B-D) 400x. All photos are
representative of 3-4 mice/group. L, lumen; mm, muscularis mucosa; M, mucin.

5.4.1.3 Rivastigmine treatment increases the thickness of the intestinal mucin
layer.
Next, the study investigates if the level of degranulation and, therefore, mucin
accumulation in the intestinal lumen differed between treatments with rivastigmine or
paraoxon. Colon tissue was collected after treatment with saline or rivastigmine or
paraoxon and processed for histological analysis. Tissue sections were stained with
Alcian blue that labels the sulphated (high acidity) complex mucins. Colon tissue
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obtained from control group showed a thin outer loose and inner adherent mucus layers
(Figure 13A) compared to the much thicker layers found in the rivastigmine- (Figure
13B) and paraoxon- (Figure 13C) treated groups. Measurements of the dense inner
layer further demonstrated a ~ 2-fold increase in its thickness following treatment with
AChE inhibitors (rivastigmine and paraoxon) compared to the control group (Figure
13D). Therefore, rivastigmine and paraoxon seem to induce the same level of
degranulation of the intestinal goblet cells.

Figure 13: Rivastigmine treatment increases the thickness of the intestinal mucin layer.
Colon from saline and rivastigmine-treated mice was collected and fixed in Carnoy’s
solution. After processing and cutting, sections were stained with Alcian Blue to
visualize mucin content. (A) Thin inner mucin layer (arrow) in the intestinal lumen of
saline-treated mice compared with a thicker inner mucin layer (arrow) present in the
lumen of (B) rivastigmine and (C) paraoxon mice. (D) Graph depicts measurements of
the thickness of the inner mucus layer in the lumen of the colon in all groups. Data are
shown as the mean ± SEM of the measurements at high power field of three nonconsecutive sections per mouse. Asterisks denote significance between control and
experimental groups (***p < 0.001). Pictures are representative of 3 slides/ mouse, 4
mice per group. Figure bars indicate 50 mm. L, lumen.
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5.4.2 Paneth cells
5.4.2.1 Rivastigmine induced degranulation of intestinal Paneth cells
Paneth cells are secretory cells unique to the small intestine and located at the base of
the intestinal Lieberkühn crypts. As goblet cells, Paneth cells contain multiple
secretory granules where different antimicrobial peptides are stored before being
release to the intestinal lumen. These cells analyzed morphologically in order to
determine if rivastigmine treatment induced any changes on them. Ultrathin sections
of ileum from saline-treated group, showed intact Paneth cells with prominent basal
nucleus, layered endoplasmic reticulum and large spherical electron-dense granules
that most of the time appear surrounded with clear halos (Figures 14A-B). When ileum
of rivastigmine-treated mice was analyzed, Paneth cells presented an abnormal
morphology containing a stressed endoplasmic reticulum, large cytoplasmic vacuoles
and fused secretory vesicles (Figure 14C). Moreover, occasionally, some Paneth cells
seemed to be completely degenerated with almost empty cytoplasm that opens to the
intestinal lumen (Figure 14D).
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Figure 14: Rivastigmine induced degranulation of intestinal Paneth cells. Transmission
electron micrograph of small intestine Paneth cells in the crypts of the small intestine of
(A-B) saline- and (C-D) rivastigmine-treated mice. (A-B) In control saline group the
cytoplasm of Paneth cells is filled with large spherical electron-dense secretory granules
(arrow) and present a well-developed endoplasmic reticulum. (C-D) In rivastigminetreated mice, Paneth cells contain fused secretory granules and have altered
morphology. ER: endoplasmic reticulum; L: intestinal lumen; N: nucleus; V: vesicles.
Bar =2 μm

5.4.2.2 Reduced lysozyme content in Paneth cells following rivastigmine
treatment
Next, study investigated if the described ultrastructural changes in Paneth cells induced
by rivastigmine correlated with the content of lysozyme, an antimicrobial protein
produced by Paneth cell and secreted upon microbial stimulation. Paraffin-embedded
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ileum sections where stained with anti-lysozyme antibody and observed by light
confocal microscopy. Results showed an intense staining in Paneth cells granules of
saline-treated mice whereas in mice treated with rivastigmine the lysozyme staining
was substantially reduced (Figure 15).
This morphological analysis of the intestinal epithelium demonstrates that both AChE
inhibitors induce degranulation of goblet and Paneth cells which could provide a
similar grade of protection against a bacterial infection.
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Figure 15: Rivastigmine reduces lysozyme levels in Paneth cells. Immunostaining with
anti-lysozyme antibody of paraffin-embeded ileum sections showed a decrease in
positively labeled (green) Paneth cells in (C-D) rivastigmine-treated mice compared
to (A-B) saline-treated control mice. In pictures B and D, the demarcated area has been
amplified and shown on the side squares. Propidium iodine (red) was used as a
counterstain to visualize cellular nucleus. L: lumen. Original magnification 400x.
Photos are representative of 3-5 mice/group/experiment.
5.5 Increased intestinal cell proliferation following rivastigmine administration
Next, it has been investigated if the increase on cell degranulation induced in Paneth
and goblet cells by rivastigmine treatment was correlated with an increase in cell
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proliferation. To study the mitotic rate of the intestinal epithelial cells, small intestine
sections were stained with an anti-Ki67 antibody (Figure 16). In both groups (saline
and rivastigmine) Ki67+ cells were found in the bottom of the crypts among the Paneth
cells, immediately above the Paneth cells and then, scatter in the lamina propria and
some in the epithelium. Although, Ki67+ cells were not quantified, intestinal tissue
from rivastigmine-treated groups seem to present a higher number of proliferating cells
at the bottom of the crypts, and in the lamina propria (Figures 16C-D) than the one
from control saline group (Figures 16A-B). These results could indicate an increase in
intestinal stem cell proliferation that will differentiate into new goblet and Paneth cells
in the intestinal epithelium replacing the ones lost after forceful degranulation.
Saline
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Figure 16: Increased intestinal cell proliferation following rivastigmine administration.
Small intestine sections of saline (A-B) and rivastigmine-treated (C-D) mice stained
with anti-Ki67 antibody to locate active proliferating cells. Small size pictures show
magnification of the demarcated areas. Hematoxylin was used as a counterstain to
visualize cellular nucleus. L: lumen. Original magnification 400x. Photos are
representative of 3-5 mice/group/experiment.
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5.6 Analysis of the immune cells present in the ileal mucosa
5.6.1 Immunohistochemical analysis
Immunohistological analysis of the intestinal mucosa was performed in order to
investigate the possible changes induced by rivastigmine treatment on the main
immune populations present in the intestinal epithelium and lamina propria. The distal
part of the small intestine (ileum) was excised, fixed and embedded in paraffin.
Sections were stained with specific antibodies against different immune populations.
5.6.1.1 CD4+ cells were more abundant in the lamina propria of the ileal mucosa
Intestine of saline (Figures 17A-B) and rivastigmine-treated (Figures 17C-D) groups
showed the presence of CD4+ T cells mostly in the lamina propria and only few of
them in the intestinal epithelium. Numerical quantification of CD4+ cells (Figures
18A-B) reveled no statistical-significant differences between the two groups, although
rivastigmine treatment reduced the number of these cells in the lamina propria and
slightly increased in the epithelium.

Saline
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Figure 17: Immunohistochemical analysis of CD4+ cells in the small intestine. Ileum
sections obtained from saline (A-B) and rivastigmine (C-D) treated mice were stained
with anti-CD4 antibody. Representative pictures are shown where positively stained
cells are brown. Arrows point to IELs. L: lumen. Scale bars= 20 m. Photos are
representative of 3-5 mice/group/experiment.

Figure 18: Quantitative analysis of the CD4+ cells in the ileal mucosa. Brown labeled
cells present in the intestinal epithelium (A) and in the lamina propria (B) of intestinal
sections were counted in 10 HPF/section and 2-3 sections/mouse, then, averaged. The
values represent the mean ± SEM of 4-5 mice/group and the results are pooled from 3
independent experiments.
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5.6.1.2 CD8+ cells preferentially located in the epithelial layer
Paraffin sections were also stained with an anti-CD8 -chain (expressed by all CD8+
cells). As shown in Figure 19, the majority of CD8+ cells are located in the
intraepithelial compartment. No differences in location were found between saline
(Figures 19A-B) and rivastigmine (Figures 19C-D) groups. Quantification of CD8+
cells (Figure 20) reveals that in saline-treated mice there were 2.75 folds more CD8+
cells in the intraepithelial compartment than in the lamina propria (Figures 20A-B).
Similarly, the intestinal epithelium of the rivastigmine-treated group contained 3.8
folds more CD8+ cells than the lamina propria (Figures 20A-B). Nevertheless, there
was no statistically significant difference in the number of CD8+ T cells in the LP or
IEL compartment between control vs. rivastigmine-treated mice.
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Figure 19: Immunohistochemical analysis of CD8+ cells in the small intestine. Ileum
sections obtained from saline (A-B) and rivastigmine (C-D) treated mice were stained
with anti-CD8 -chain antibody. Representative pictures are shown where positively
stained cells are brown. Hematoxylin was used for counterstain. Original
magnification 200x (A-C) and 400x (B-D). L: lumen. Photos are representative of 3-5
mice/group/experiment.

63

Figure 20: Quantitative analysis of CD8+ cells in the intestinal mucosa. Brown labeled
cells (CD8+) present in the intestinal epithelium (A) and in the lamina propria (B) of
intestinal sections were counted in 10 HPF/section and 2-3 sections/mouse, then,
averaged. The values represent the mean ± SEM of 4-5 mice/group and the results are
pooled from 3 independent experiments.

5.6.1.3 Macrophages were only detected in the lamina propria of the intestinal
mucosa
By immunohistochemistry, the presence of macrophages identify using an anti-F4/80
antibody. Despite the high background obtained with this antibody, results showed few
F4/80+ cells in the intestinal lamina propria of saline (Figure 21A) and rivastigminetreated mice (Figure 21B). When positive cells were quantified, no significant
differences between the two groups were found (Figure 21C). No F4/80+ cells could
be observed in the intraepithelial compartment.
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Figure 21: Presence of macrophages in the intestinal lamina propria. Ileum sections
obtained from (A) saline and (B) rivastigmine-treated mice were stained with antiF4/80 antibody to detect macrophages, and counterstained with hematoxylin.
Representative images of 3-5 mice/group/experiment are shown. Original
magnification 400x. L: lumen. (C) F4/80+ cells were counted in 10 HPF/section and
2-3 sections/mouse, then, averaged. The values represent the mean ± SEM of 4-5
mice/group and the results are pooled from 2 independent experiments.

5.6.1.4 Abundant presence of IFN-producing cells in the ileal mucosa
Given the critical role of IFN in resistance to Salmonella infection (Ingram, Brodsky,
& Balachandran, 2017) the presence of IFN-producing cells analyzed in the mucosa
of the ileum by immunohistochemistry. In both the saline and rivastigmine groups,
IFN+ cells were observed within the epithelial layer at the basolateral surface of
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adjacent epithelial cells and in the lamina propria (Figure 22). Rivastigmine treatment
seems to increase the number of IFN+ cells (Figure 22B) compared to the saline group
(Figure 22A). This was based on quantification of the number of IFN+ cells in both
compartments. Based on the staining, it was difficult to accurately determine whether
these cells were in the LP or in the epithelial layer. This fact was partially confirmed
by quantification of IFN+ cells in the tissue sections, although the increment did not
reach statistically significant difference (Figure 22C).
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Figure 22: IFN producing cells in the small intestine mucosa. Ileum sections obtained
from (A) saline and (B) rivastigmine-treated mice were stained with anti-IFN
antibody and counterstained with hematoxylin. Representative images (600x) from
two independent experiments (four mice/group/experiment) are shown. L: lumen. (C)
Quantitative estimation of the number of IFN cells in intestinal sections of saline and
rivastigmine groups. Data are shown as the mean ± SEM of the number of positive
cells per high power field. The values represent the mean ± SEM of 4-5 mice/group
and the results are pooled from 2 independent experiments.
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5.7 Phenotypic characterization of the immune population in the intestinal
epithelium and lamina propria following rivastigmine or paraoxon
administration.
In order to see if there is any difference between the effect of paraoxon and
rivastigmine treatment on the immune population, further investigated the phenotypic
composition of the immune cells present in the intestinal mucosa by flowcytometry.
The intestinal tissue was excised from mice treated with either saline, paraoxon or
rivastigmine, and processed for isolation of two populations of lymphoid cells based
on their location: intraepithelial lymphocytes (IELs) and lamina propria leukocytes
(LPLs). Representative dot plots with gating strategy for IELS from each group (saline,
rivastigmine and paraoxon) are shown in Figures 23 and 24. Date from rivastigmine
group are preliminary as it is based on one experiment only. For the saline and
paraoxon groups, the data is representative of 3 experiments.

Figure 23: Gating strategy for intraepithelial T cells. CD3+ intraepithelial cells of saline, paraoxon
and rivastigmine were analyzed for CD4 and CD8 positivity. CD8+ cells were further analyzed for
the expression of  or  chain, and two population were discerned CD8+ and CD8+.
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Figure 24: Gating strategy for intraepithelial myeloid cells. CD45+ intraepithelial cells of saline, paraoxon and
rivastigmine were analyzed for CD19 and CD11b positivity. CD11b+ cells were further analyzed for the expression
of Ly6G and Ly6G molecules. Ly6C-Ly6G- population were further analyzed for the expression of MHCII
activation marker. Representative dot plots for individual mice of each group are shown.
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Analysis of immune cell populations in the intestinal epithelium of saline-treated mice
revealed that almost 80% of the haemopoietic (CD45+) cells are T cells (CD3+) with
much lower percentage of B cells (CD19+) and myeloid cells (CD11b+) (Figure 25AD). Rivastigmine (Figure 25D) or paraoxon (Figure 25A) treatment did not induce any
change in any of the major cell populations, except a significant reduction in myeloid
cells of paraoxon treated group (Figure 25A). In all three groups, cytotoxic
lymphocytes (CD8+) constituted the majority of T cells (11-fold more than CD4+ or
double positive cells) (Figures 25B-E). CD8 is a cell surface dimeric glycoprotein that
can be expressed as a heterodimer (CD8 with CD8) or as a homodimer (two CD8
chains). In saline-treated mice, CD8+ cells represent 56% compared to 40% of
CD8+ (Figures 25C-F). Paraoxon treatment did not change the proportion between
these two subpopulations (Figure 25C), however, rivastigmine treatment induced a
statistically significant increase in the percentage of CD8+ cells (naïve CD8 cells)
and, consequently a decrease in the CD8+ population (Figure 25F). Finally, looked
at the myeloid populations present in the intestinal epithelium compartment and
observed that the majority of the CD11b+ cells were Ly6C-Ly6G- in all groups (~75%
in saline and paraoxon; ~85% in rivastigmine group) which represented ~ 5% , 4% and
6% of the total CD45+ cells, respectively (Figures 26A-C). Only rivastigmine
treatment significantly increased the percentage of myeloid cells in the intestinal
epithelium (Figure 26C). When the activation state was analyzed, it observed that
~40% of the Ly6C-Ly6G- cells expressed MHC class II in the saline group (Figures
26B-D). This percentage was not altered after paraoxon (Figure 26B) or rivastigmine
administration (Figure 26D).

Figure 25: Rivastigmine treatment but not paraoxon increased significantly the percentage of CD8αβ+ T
cells in the intestinal epithelium. Most of hematopoietic cells in IELs are CD3+ cells. Majority of these cells
are CD8+ cells. Treatment with paraoxon (A, B, C) or rivastigmine (D, E, F) did not make any change in
either the percentage of these population nor the phenotype.
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Figure 26: Rivastigmine treatment but not paraoxon increase significantly Ly6CLy6G- myeloid cells in the intestinal epithelium. The majority of myeloid cells are
Ly6C-Ly6G-. MHC+ molecule represent around 41% of these cells. Treatment of
paraoxon (A-B) did not change the percentage of these cells. Rivastigmine treatment
(C-D) significantly increase the percentage of Ly6C-Ly6G- and no change in the
expression of MHC+.

Analysis of the same lymphoid populations in the lamina propria (see Figures 27 and
28 for gating strategy), revealed that the percentages of the different CD45+ cell
populations were different to the ones in the epithelium. The percentage of T cells
(CD3+) was lower (~40%) and the percentage of B cells and myeloid cells was
increased to ~9% and ~26%, respectively, in saline group (Figures 29A-D). In this
group, T cells were distributed: ~50% CD8+, ~20% CD4+ and ~17% CD8+CD4+
(Figures 29B-E). Paraoxon treatment induced a significant increase in the percentage
of T cells compared to saline (Figure 29A), that was not detected after rivastigmine
treatment (Figure 29D). However, both treatments resulted on higher percentage of
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CD8+ cells and, lower percentage of CD4+ and CD4+CD8+ cells (Figures 29B-E). In
all groups, ~50% of the CD8+ cells expressed CD8 and the other half CD8 (
Figures 29C-F). Similar to what was observed in the epithelium compartment, ~80%
of the CD11b+ cells in the lamina propria were Ly6C-Ly6G- in all the three groups,
representing ~7% of the hematopoietic CD45+ cells. Only treatment with paraoxon
reduced the percentage of Ly6C-Ly6G- cells expressing MHC class II (Figure 30B).
Rivastigmine treatment did not induced any change in MHC class II expression in
comparison to the saline treatment (Figure 30D).

Figure 27: Gating strategy for T cells in the lamina propria. CD3+ intraepithelial cells of saline, paraoxon and
rivastigmine were analyzed for CD4 and CD8 positivity. CD8+ cells were further analyzed for the expression of  or
 chain, and two population were discerned CD8+ and CD8+. Representative dot plots for individual mice of
each group are shown.
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Figure 28: Gating strategy for myeloid cells in the lamina propria. CD45+ intraepithelial cells of saline, paraoxon and
rivastigmine were analyzed for CD19 and CD11b positivity. CD11b+ cells were further analyzed for the expression of
Ly6G and Ly6G molecules. Ly6C-Ly6G- population were further analyzed for the expression of MHCII activation marker.
Representative dot plots for individual mice of each group are shown.
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Figure 29: Paraoxon treatment increased the percentage of CD8+ cells in the lamina propria. Most of hematopoietic
cells in LPL are CD3+ cells. Majority of these cells are CD8+ cells. Treatment with paraoxon (A-B-C) increase
significantly the CD3+ and CD8+ cells. Rivastigmine treatment (D-E-F) did not make any significant change in
either the percentage of these population nor the phenotype.
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Figure 30: Paraoxon treatment decreased the expression of MHCII+ in lamina propria
myeloid cells. The majority of the myeloid cells are Ly6C-Ly6G-. MHC+ molecule
represent around 42% of these cells. Treatment with paraoxon (A) did not change the
percentage of Ly6C-Ly6G- cells, However MHC expression decrease significantly in
these cells (B). Rivastigmine treatment (C) did not change the percentage of Ly6CLy6G- cells and no change in the expression of MHC+ (D).

These results indicate that paraoxon and rivastigmine induced different effects on the
immune population in the intestinal mucosa. Paraoxon induced an increase in the
percentage of CD8+ cells and a downregulation in the activation markers on DCs
(Ly6C-Ly6G-) in the lamina propria. In contrast, although there was no significant
change in the total percentage of lamina propria CD8+ cells, rivastigmine-treatment
induced a shift in the phenotype of conventional CD8+ cells by increasing the
percentage of CD8++ in the epithelium.
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Chapter 6: Discussion
Previously, it was demonstrated that exposure to paraoxon, a highly specific AChE
inhibitor, enhanced survival of orally infected mice with a virulent strain of Salmonella
enterica serovar Typhimurium (Fernandez‐Cabezudo et al., 2010). In further studies
(Al-Barazie et al., 2018), it was shown that this protection was correlated with
decreased bacterial load in systemic target organs, like spleen and liver, and mediated
by an enhanced innate immune responses in the intestinal mucosa. This study reported
that cholinergic stimulation induced the degranulation of intestinal secretory cells,
goblet and Paneth cells, enhancing the innate immune defenses at the intestinal barrier
and preventing the translocation of bacteria to systemic organs (Al-Barazie et al.,
2018). The current study is aimed to investigate whether rivastigmine, a more
physiological ACh inhibitor, can also protect against an oral infection with virulent
Salmonella.
In order to monitor the effectiveness of rivastigmine as AChE inhibitor, the activity of
AChE in blood after 24 hours of its administration measured (data not shown), but
could not detect any AChE inhibition. In agreement with showed results, a recent study
reported no changes in the AChE activity in plasma of adult mice exposed to various
concentrations of rivastigmine (Basaure, Peris-Sampedro, Cabré, Reverte, &
Colomina, 2017). This is probably due to the short half-life in plasma that rivastigmine
has, only 1 hour, and its pharmacodynamic effect of only 10 hours (Schmeltz &
Metzger, 2007). It has been reported that cholinergic stimulation induces a transient
hyperactive behavior in animals as well as faster peristaltic movements, which lead to
a retarded body growth in young treated animals (Al-Barazie et al., 2018; George et
al., 2016; Satapathy et al., 2011; Stahl, 2006). Thus, animals’ body weight followed in
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order to monitor the rivastigmine treatment. Results confirmed a slower body growth
during the treatment period with rivastigmine indicating an effective cholinergic
stimulation. In agreement with these results, AChE inhibition induced by paraoxon
treatment also reduced significantly the body weight growth (Al-Barazie et al., 2018;
Fernandez-Cabezudo et al., 2008; Fernandez‐Cabezudo et al., 2010). Knowing that
rivastigmine treatment was effective, study aimed to see if this treatment could
enhance survival of mice orally infected with virulent Salmonella. Surprisingly,
rivastigmine treatment did not protect the mice from the lethal infection and all mice
died by day 23 post-infection. However, rivastigmine treatment significantly enhanced
survival compared to the control saline-treated mice where the survival time was 11
days.
To gain further insight, bacterial load at mucosal sites investigated (intestine, feces and
intestinal content) and systemic organs like spleen and liver, at day 3 post-oral
infection with high dose of Salmonella. Data showed that in rivastigmine-treated mice
most of the bacteria were located in feces and intestinal content with few in the
systemic organs. The opposite was found in saline-treated mice where spleen and liver
presented higher bacterial load than feces and intestinal content. However, the
bacterial load in the whole intestine (tissue + bacterial content) was similar in both
groups (saline and rivastigmine). The fact that, in the saline-treated group, low number
of bacteria were found in the intestinal content compared to the number in systemic
organs could indicate that Salmonella in this group was already translocated from the
intestinal lumen to the intestinal mucosa which also explains the presence of higher
number of bacteria in the systemic organs. On the other hand, in rivastigmine-treated
mice most of the bacterial load found in the whole intestine seemed to be located in
the intestinal content which could indicate a stronger intestinal barrier and, therefore,
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more difficulties for Salmonella to penetrate the intestinal mucosa and disseminate to
systemic organs.
Results suggest that rivastigmine treatment is able to initially control bacterial
translocation across the mucosa and effectively delay bacterial dissemination into the
spleen and liver. However, this effect appears to be rather transient because pathogenic
bacteria were able to eventually cross the epithelial barrier and disseminate into
systemic organs. In contrast, paraoxon was able to effectively inhibit bacterial
translocation and block their dissemination, and hence improving log-term host
survival (Al-Barazie et al., 2018). To try to explain these different treatment outcomes
after Salmonella infection, study focus into the mechanism of action of each of two
AChE inhibitors. Both paraoxon and rivastigmine target the cholinesterases AChE and
BChE (butyrylcholinesterase) and are able to cross the blood-brain barrier. Paraoxon
is an irreversible cholinesterase inhibitor with a plasma half-life of 20 hours, and binds
to the active site of the enzyme making it unable to hydrolyze ACh (Musilova, Kuca,
Jung & Jun, 2009). On the other hand, rivastigmine is a non-competitive reversible
cholinesterase inhibitor with a plasma half-life of 1 hour, although it has a longer action
in the brain (Hofmann, Hock, Smelser, & Baltes, 2001; Schmeltz & Metzger, 2007).
The reversible mode of its binding to the AChE enzyme allows rivastigmine to quickly
dissociate from the enzyme, which in turn regains its function of hydrolyzing ACh,
leading to a reduction in the levels of ACh. However, paraoxon binds in an irreversible
manner, through strong covalent bonds, to the catalytic site of the AChE enzyme,
preventing its action on ACh, and, therefore, increasing the levels of ACh. So, as
speculation, lower levels of ACh available in rivastigmine-treated mice compared to
paraoxon-treated mice leads to reduced cholinergic stimulation and lower protection
against oral bacterial infections.
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Next, wanted to see if rivastigmine treatment had any effect on the intestinal mucosal
epithelial cells as their proper function and integrity is essential for the elimination of
microbes. Absorptive enterocytes, goblet cells, Paneth cells and enteroendocrine cells
constitute the majority of cells in the intestinal mucosal epithelium (Kim & Ho, 2010).
In this study, two of these types of mucosal epithelial cells analyzed, goblet and Paneth
cells. Results showed that rivastigmine treatment clearly induced degranulation of
goblet and Paneth cells and increased the mucus barrier in the intestinal lumen. These
findings are similar to what previously reported with paraoxon (Al-Barazie et al.,
2018).
Goblet cells represent a major cellular component of the innate defense in the intestine
and play an important role in maintaining the intestinal homeostasis (McCauley &
Guasch, 2015). They are responsible for the secretion of mucins, one of the
components of the mucus barrier. Several factors control the release of mucins in the
intestine including autonomic neural pathways mediated by cholinergic receptors on
goblet cells (Specian & Neutra, 1980). Mucin secretion from goblet cells was found to
be abrogated by atropine (reversible antagonist of the muscarinic acetylcholine
receptors) indicating that the effect of ACh on mucus secretion is mediated by
muscarinic receptors (Specian & Neutra, 1982). The presence of a mucus layer in the
intestinal lumen is an extremely important defense mechanism against oral pathogens
like Salmonella, as the bacteria get trapped and removed by peristalsis, avoiding their
adhesion to the surface of the epithelium (Elphick & Mahida, 2005). So, the increase
on mucins secretion by cholinergic stimulation induces the accumulation of mucus in
the intestinal lumen and, therefore, increases the mucus barrier which is the first line
of defense against bacterial infection. Results showed a significant increase in the
thickness of the mucus layer in the lumen of colon tissue following rivastigmine
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treatment compared to tissue from saline-treated mice. Moreover, both AChE
inhibitors (rivastigmine and paraoxon) observed to induce a comparable accumulation
of mucus.
As mentioned above, data also showed that rivastigmine treatment induced
degranulation of Paneth cells and release of lysozyme. Paneth cells are important in
the innate intestinal defense as they contribute to the extra-epithelial defense barrier
by secreting antimicrobial proteins and peptides (AMPs) such as lysozyme and
defensins. Paneth cells contribute to regulate the intestinal microbial density and to
the protection of the stem cells also located in the crypts of Lieverkuhn (Elphick &
Mahida, 2005). Upon exposure to bacteria or bacterial products, Paneth cells release
the AMPs to the intestinal lumen in order to control microbial growth and prevent
microbial invasion into the crypt (Ayabe et al., 2000). A recent study reported the
presence of mAChR (M2) in the intestinal crypt, probably present on the Paneth cells
(Muise, Gandotra, Tackett, Bamdad, & Cowles, 2017) although a more extensive
investigation is needed. Results suggest that rivastigmine treatment induces a more
robust defense barrier in the intestinal lumen containing more mucin to trap bacteria
and more lysozyme to fight against pathogens. This mechanism could explain the
initial protection that rivastigmine treatment exerted on Salmonella-infected animals
where bacteria was present mostly in the intestinal content and feces, and almost absent
from systemic organs. Previously reported similar results using paraoxon as AChE
inhibitor (Al-Barazie et al., 2018). However, while paraoxon treatment induced long
term protection in 80% of the mice following a lethal Salmonella infection,
rivastigmine treatment prolonged animal survival by up to 11 days, after which all
mice succumbed to the infection. This indicates that the reinforcement of the luminal
barriers induced by cholinergic stimulation is not enough to protect mice from a lethal
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bacterial infection. Therefore, decided to look at the possible effect that treatment with
AChE inhibitors exerted on the intestinal mucosa (epithelium and lamina propria)
where the innate and adapted immune responses to invading pathogens take place.
The epithelial layer in the intestine is considered a barrier that protects and avoids the
entrance of microbiota and food antigens inside the body. When a pathogen breaks this
barrier a disruption in the normal balance of the intestine takes place which triggers a
coordinated immune response to eliminate the pathogen. S. Typhimurium successfully
invades the host and stablishes an infection by disrupting the tight junctions that
maintain the epithelial cells closely adhered (Ashida, Ogawa, Kim, Mimuro, &
Sasakawa, 2012) to promote its translocation to the intestinal lamina propria. In the
lamina propria, S. Typhimurium will encounter many different types of effector cells
including B cells, T cells, dendritic cells, macrophages and natural killer cells that will
coordinate an effective immune response (Patel & McCormick, 2014). As part of this
immune response, effector cells activated in the MLN by DCs migrated from PP will
arrive to the lamina propria. Additionally, resident immune cells in the lamina propria
will be able to mount an initial an immediate immune response.
First, looked at the spatial location of the main lymphoid cells in the intestinal tissue
by immunohistochemistry and results showed that the main lymphoid populations are
located, as expected, in the intestinal mucosa which is comprised by the epithelium
and the lamina propria.
Quantitative analysis of staining reveled that in the epithelium, CD8+ cells were the
most abundant T cell population with few CD4+ T cells (~4:1 ratio) in both groups,
saline and rivastigmine. In the lamina propria, much lower number of CD8+ cells were
present and a discreate higher number of CD4+ T cells compared to the epithelium
compartment. Although no significant differences were found between saline and
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rivastigmine group, a slight increase noticed in the number of T cells (CD4 and CD8)
present in the epithelium and a slight decrease in the lamina propria, after rivastigmine
treatment. Few macrophages could only be observed in the lamina propria with no
differences between saline and rivastigmine groups.
In a detailed phenotypic analysis of the immune cells that populate each of the effector
compartments of the intestinal mucosa (epithelium and lamina propria), not only
saline and rivastigmine-treated groups included but also mice treated with paraoxon in
order to see if could detect any difference between paraoxon and rivastigmine
treatment that could explain the different levels of protection against oral Salmonella
infection. The intestinal epithelium contains not only the typical columnar cells but
also a population of lymphocytes named intraepithelial lymphocytes (IELs) (Paul,
2003) located between the basolateral surface of the epithelial cells. IELs are
continuously exposed to antigens that cross the epithelial barrier and, therefore,
participate in the induction and regulation of the immune response in the intestinal
mucosa. T cells, specially CD8+ cells in the intestinal epithelium provide the first line
of immune defense against invading pathogens (Jabri & Abadie, 2015). The intestinal
epithelium contains one of the most abundant T cell populations in the body which are
responsible for the continuous surveillance of the intestine in order to maintain the
homeostasis and prevent the entrance of microbes and food particles (Van
Konijnenburg et al., 2017).
In agreement with previous studies (Cheroutre, 2004; Guy-Grand et al., 1991;
Lefrancois, 1991; Lin et al., 1994), results showed that in the saline control mice, the
majority of the IELs were T cells which around 80% expressed CD8 and only 15%
CD4. Neither rivastigmine nor paraoxon treatment changed the percentage of CD8+
cells in the epithelium compartment, compared to the saline control treatment.
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However, the proportion of CD8+ cells decreased after rivastigmine treatment
inducing an increase in the percentage the CD8+ population.
The presence of CD8 effector memory cells are essential for a rapid control of any
pathogens invading the intestinal mucosa. Two types of CD8 T cells were found
among the IELs: CD8 homodimer and CD8 heterodimer. CD8+ cells are T
cells that have been activated in the lamina propria or MLNs and then, migrated to the
epithelium where their function is to protect the mucosal barrier either as a effector
cells or tissue resident memory T cells (Montufar‐Solis, Garza, & Klein, 2007). They
have been reported to express strong cytotoxic T lymphocyte (CTL) activities and
produce large amounts of IFN-γ upon TCR-dependent stimulation (Emoto, Emoto, &
Kaufmann, 1996). Intraepithelial CD8+ T cells are also TCR+ and express
constitutively granzyme B, CD103 (integrin 7), CD69 and produce lower amounts of
TNF and IFN than conventional CD8 T cells (Masopust, Vezys, Wherry, Barber, &
Ahmed, 2006). In the other hand, CD8+ T cells are functionally distinct population
with the capacity to produce greater levels of TNF and IFN upon stimulation, and
perforin than their CD8+ counterparts (Walker et al., 2013). Therefore, results
suggest that by reducing the percentage of CD8+ IELs, rivastigmine treatment
induced a deficit of professional fast-responder CD8 T cells that rendered the host
more susceptible to pathogen invasion.
Histological study also showed the presence of IFN producing cells mostly located at
the base of the epithelium and few in the lamina propria. IFN is produced not only by
T lymphocytes but by other several immune cells including macrophages, NK cells,
NKT cells (Rhee, Walker, & Cherayil, 2005). Another important cell type in the
intestinal mucosa are the innate lymphoid cells (ILCs) which are a novel family of
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tissue resident cells (Ebbo, Crinier, Vely, & Vivier, 2017; Mjösberg & Spits, 2016)
that lack antigen-specific receptor. They are able to detect any changes that may occur
in the microenvironment and respond by secreting cytokines. Specifically, ILC1s
secrete IFN in response to IL-12, IL-15 and IL-18 (Panda & Colonna, 2019) and are
the most abundant type of ILCs in the intraepithelial compartment (Han et al., 2019).
The potential role that the neuronal system could play in the activation of ILCs to
produce cytokines has been indicated but not confirmed (Han et al., 2019). As
speculation, in this study the IFN-producing cells detected in the intestinal mucosa
could be CD4+ cells, CD8+ ( or ) cells or ILC1s, but further experiments are
needed to clarify this point.
Lamina propria is the layer of connective tissue underlying the intestinal epithelium.
Its cellular population differs from the epithelium in that it contains more B cells, more
CD4+ cells, more myeloid cells and the presence of new additional sub-population of
CD8+ cells, CD8+ TCR+ T cells that was absent in the epithelium compartment.
TCR+ cells are usually defined as CD8+ or CD8- (Hayday, Theodoridis,
Ramsburg, & Shires, 2001; Vantourout & Hayday, 2013) but not CD8+. Only in
TCR -/- mice CD8+ TCR were described (French, Roark, Born, & O'Brien, 2009)
and, more recently in humans where were identified in blood and, intestine (Kadivar,
Petersson, Svensson, & Marsal, 2016). This CD8+ T cell subset expresses cytotoxic
mediators, responds to IL-2, produces IFN and TNF and they may play a role in the
gut homeostasis and mucosal healing in bowel diseases (Kadivar et al., 2016). In this
model, a more exhaustive analysis of the lamina propria immune populations is needed
to be able to detect this controversial subpopulation.
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This results also showed that ACh inhibition with paraoxon increased the percentage
of the total T cell population compared to the control, but not rivastigmine. CD8+ cells
are responsible of this increase in T cells and, it could be due to a recruitment of CD8+
cells to the lamina propria or to an active proliferation of existing CD8. The presence
of more CD8+ cells indicates an increase in the surveillance and recognition capacity
which allows a more rapid and efficient response to any invading pathogen. It has been
shown that CD8+ T cells are essential for survival to primary infection with Y.
enterocolitica CD8+ and prevent early systemic dissemination of the bacteria (Siefker
& Adkins, 2017).
On the other hand, rivastigmine treatment did not increase the percentage of total T
cells but increased the percentage of CD8+ cells among the T cell population and,
therefore, decreased the percentage of CD4+ and double positive CD4+CD8+ cells.
Knowing the important role that CD8+ cells play in Salmonella clearance (Hess, Ladel,
Miko, & Kaufmann, 1996), an increase on these cells will suppose an advantage for
the host.
It is good to mention that the changes induced on immune cells by AChE inhibitors
can be due to direct effect (ACh+ AChR) or indirect (cytokine driven). Without
discarding the possibility that the increase of mucus secretion and AMP induced by
AChE administration would have also altered the microbiota composition in the
intestine which could influence the development of some T cell populations.
Paraoxon treatment, but not rivastigmine, showed to have an effect downregulating
the expression of MHCII on lamina propria resident DCs while no changes were
detected on this population after rivastigmine exposure. The major histocompatibility
complex class II molecules (MHC-II) are constitutively expressed by immune antigenpresenting cells (APCs) like B cells, monocytes, macrophages and dendritic cells
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(DCs). MHC-II molecules are essential for the initiation of the antigen-specific
immune response during which APCs, specially DCs, present processed antigens to
naïve CD4+ T cells and, therefore, stimulate them. In the intestinal lamina propria
resident DCs (Ly6C-Ly6G-) founded that patrol their microenvironment searching por
antigens that internalize to generate complexes peptide-MHCII that eventually will be
present to a naïve T cell (Trombetta & Mellman, 2005). During Salmonella infection,
DCs recognize LPS or flagellin, antigens expressed on Salmonella, and respond by
increasing the expression of MHC class II and the co-stimulatory molecules CD80,
CD86, and CD40 (McSorley, Ehst, Yu, & Gewirtz, 2002; Salazar-Gonzalez et al.,
2007), therefore, resting unstimulated cells could be of more use to fight a new
infection than already stimulated ones. Downregulation of the MHC-II molecules
expression on DCs present in the lamina propria found in paraoxon-treated mice can
also be explained by (1) the presence of a more robust luminal barrier (with more
mucins and AMP) that leads to less antigens transposing the epithelial barrier and (2)
the presence of more CD8+ cells that will take over the immune defense of the lamina
propria. Despite the fact that rivastigmine treatment also induced a stronger luminal
barrier, could not appreciate any MHC-II downregulation in DCs.
This study did not analyze the innate lymphoid cells (ILCs). Although it is well known
that ILCs are important regulators of early infection at mucosal barriers and they
provide an immediate immune response through the production of cytokines that limit
pathogen invasion (Colonna, 2018). In future studies one of the plans to evaluate the
effect of cholinergic stimulation on these immune populations.
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Chapter 7: Conclusions
Rivastigmine treatment enhanced host survival after a lethal oral infection. The
observed effect seems to be partially due to an increased in degranulation of goblet
and Paneth cells in the epithelium of the GI tract which enhanced the innate immune
mucosal defense mechanism as showed in Figure 31C. This could explain the
reduction in the initial bacterial translocation and systemic dissemination of oral
Salmonella leading to enhanced survival. However, rivastigmine treatment failed to
increase the total CD8+ population in charge of surveillance as it was observed in mice
treated with paraoxon.
To conclude, protection against lethal bacteria in the GI tract depends on the extent of
cholinergic pathway activation induced by AChE inhibitors. Cholinergic stimulation
with rivastigmine induced a deficit of professional fast-responder CD8 T cells
within the intestinal epithelium, which could render the host more susceptible to
pathogens. In the lamina propria, rivastigmine treatment did not induce any significant
change in the CD8+ population (Figure 31C). In contrast, paraoxon increased the total
CD8+ population in charge of surveillance which facilitates a more rapid and efficient
response to invading pathogens (Figure 31B).
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Figure 31: Effect of AChE inhibition on the intestinal mucosa. Schematic
representation of the intestinal immune defense in mice treated with (A) saline, (B)
paraoxon and (C) rivastigmine.
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7.1 Future directions
Many different experiments have been left for the future due to lack of time, and some
questions need to be answer. Such as, what is the mechanism by which ACh modulates
CD8+ cells in the intestinal lamina propria? What is the effect of cholinergic
stimulation on other immune cell populations like DCs and ILCs? How cholinergic
stimulation modulates the response of these populations to an in vivo infection? In
order to administer these questions, the aimed will be to:
•

Study the effect of AChE inhibitors on the intestinal immune population
after infection.

•

Investigate the different CD8+ subpopulations based on the different TCR
expression as well as the intestinal innate lymphoid cell (ILC) population
and their role in protection against infection.

•

Study, in vitro, the effect of ACh on CD8 T cell differentiation and
proliferation.
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